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The prostate cancer (PCa) microenvironment is profoundly immunosuppressive and 
infiltrating immune cells (e.g. CD8 T cells, NK cells) become anergic or suppressive. 
Immunosuppression is thought to be a key factor in PCa progression and the site of the 
cancerous prostate is where the immune system is most compromised.  
We hypothesize that PCa can progress by tolerance to, and evasion of tumour cells from the 
immune system, and that therapies that act within the immunosuppressive PCa environment 
to reverse this immunosuppression are therefore desirable. 
 
A coculture system of human non-adherent peripheral blood mononuclear cells 
(PBMCs) and PCa cell lines was set up, where IL-15 was found to be the most potent activator 
of NK and NKT cells, inducing the expansion of these cells, and the NK- mediated killing of the 
PCa cells. Other therapeutic Th1 cytokines had no effect within this environment.  
Based on these results, the mechanisms of action of IL-15 on effector cell mediated killing of 
PCa cells in these coculture models were further investigated, by looking at its ability to 
modulate NK receptor and NK receptor ligand expression and interaction. It is shown that IL-
15 enhances the NK cytotoxicity towards the PCa cells by upregulating the NKG2D receptor 
expression and downregulating both the surface and soluble expression of its ligand MICA.  
 
A key focus of this project was to create novel immunotherapeutic agents that can be 
localised in the prostate and to determine their efficacy. Having identified IL-15 as a cytokine 
that uniquely activates NK cells within PCa-effector cell cocultures, the technique of cytotopic 
tailing was used; this enabled the modification of recombinant human IL-15 and two 
antibodies to immune checkpoint inhibitors into a cytotopic form, whereby they can attach 
to the cell membrane and exert their functions more efficiently and for a prolonged period of 
time. The activity and function of tailed IL-15 and of the two tailed antibodies were tested in 
vitro as well as in an in vivo tumour challenge model of C57BL/6 mice injected with TRAMP-
C2 tumour cells. Complete tumour clearance was observed in mice that were treated with 
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1.1 Nature of cancer and epidemiology 
The introduction of vaccination, antibiotics and other preventive measures have 
clearly contributed to the reduction of the mortality rates due to infectious diseases during 
the last century, while the incidence of cancer has dramatically increased , making it a global 
health issue (Jemal, Bray et al. 2011) . Cancer is a disease defined by the uncontrollable 
replication of cells, caused by altered genes. Those genes are functionally categorised into 
two groups, oncogenes and tumour suppressor genes (Hanahan and Weinberg 2011). 
In the UK, around 300,000 new cases of cancer were registered in 2014, of which most were 
in males; out of 200 different types of cancer, breast, lung, colorectal and prostate were the 
most common, accounting for more than 50% of all cancer cases (Murphy 2016, Siegel, Miller 
et al. 2016). 
 
1.1.1 The prostate 
The adult prostate resembles the shape of a walnut and weighs around 18g (Wein 
2012). It is a firm rubbery gland, located at the base of the bladder, surrounding the posterior 
urethra. It is situated posterior and inferior to the symphysis pubis, superior to the urogenital 
diaphragm and anterior to the rectal ampulla (Figure 1.1). McNeal has described several 
different zones of the prostate. This model is still used in the contemporary literature with 
some modifications: a) the central zone around the urethra which forms 5-10% of the 
glandular tissue in young men, b) the transition zone that can enlarge later in life and cause 
bladder outflow symptoms, c) the peripheral zone which comprises 75% of glandular volume 
in the adult prostate and where majority of prostate cancers have been shown to arise. 
Another zone is d) the anterior fibromuscular stroma which has little significance generally 
and contains little glandular tissue. The main tissue types that form the prostate gland are 
the epithelial tissue, containing secretory glandular cells, non-secretory basal cells and 
neuroendocrine cells and the stromal compartment containing various cell populations, such 






Figure 1.1: Anatomy of the prostate: a) McNeil’s four different zones of the prostate are shown. The 
transition zone lies proximal to the ejaculatory ducts and ventral and dorsal to urethra. The central 
zone surrounds the ejaculatory ducts. The peripheral zone constitutes the bulk of the apical, posterior 
and lateral aspects of the prostate. The anterior fibromuscular zone covers the transition zone and 
the distal urethra ventrally. Photo adapted from Hinman’s Atlas of Urosurgical Anatomy (MacLennan 
2012) b) Diagram showing a coronal section of the prostate. PZ: peripheral zone, TZ: transition zone, 
UP: proximal urethral segment and periurethral glands,V: verumontanum, s: preprostatic sphincter, 




1.1.2 Background to Prostate cancer: Epidemiology and Treatment  
Prostate cancer (PCa) is the most frequently diagnosed cancer and the second most 
common type of cancer causing death in men, after the first killer which is lung cancer, in the 
UK. Every year, more than 45,000 men are diagnosed with PCa and it is thought that 1 in 8 
men will develop it at some point in their lives. In Europe, PCa is the third most common 
cause of cancer and the sixth most common cause of cancer death overall (McLaren 2016, 
Murphy 2016).    
 
PCa is a generally slowly progressing disease, which over time could metastasize, as the 
cancer cells develop alterations in their shape and in their attachment to other cells and to 
the extracellular matrix, losing the expression of adherence molecules (e.g. E-cadherin) and 
undergoing epithelial- mesenchymal transition (Hanahan and Weinberg 2000, Hanahan and 
Weinberg 2011). The most significant factor for developing the cancer is age (75% of PCa 
cases are diagnosed in men over the age of 65) (Siegel, Naishadham et al. 2012), since aging 
is associated with a number of physiological changes, such as faulty DNA repair mechanisms, 
immunosenescence and alterations in hormone levels. These changes aid the structural 
remodelling of prostate cells leading to modifications in gene expression, which affect cellular 
processes, such as apoptosis and proliferation. These result in stromal changes in the 
prostate gland, enhancing the tumour growth, and as the cancerous prostate is very 
immunosuppressive the tumour progresses further (Barron and Rowley 2012). 
  
Prostate carcinomas express a range of cell markers, including androgen receptors and 
protein specific antigen (PSA). The latter is present in small quantities in the serum of healthy 
men. An elevation of PSA levels should be investigated, hence the PSA testing in addition to a 
Digital Rectal Examination (DRE) are the early PCa screening tools currently used. Definitive 
diagnosis is done by histopathological verification on a prostate biopsy, except in the case of 
a clearly abnormal DRE, or of metastasis on a bone scan or of a very high PSA; then the 
histology is often not needed.  
Prostate cancer grading system uses Gleason scoring (GS) as it was developed by Donald 
Gleason. This system assigns each histological sample with a pattern ranging from 1 to 5 and 
the addition of the most prevalent and the second most common scores, provides the grade 
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which could range between 2 and 10. To date, the Gleason grading system has been revised 
twice, in 2005 and 2014; however it has presented many weaknesses that impacted on 
patient care, and as it seemed critical to design a new grading system Epstein et al in 2013, 
proposed a more accurate and simplified grading system. In that, five grade groups were 
presented, based on the histological examination of the samples: "Grade group 1 (GS 3+3=6) 
was given to individuals with discrete well-formed glands; group 2 (GS 3+4=7) was given to 
those with predominantly well-formed glands with lesser component of poorly 
formed/fused/cribriform glands; group 3 (GS 4+3=7), to those with predominantly poorly 
formed/fused/cribriform glands with lesser component of well-formed glands; group 4 (GS 8) 
to those with either poorly formed/fused/cribriform glands, or predominantly well-formed 
glands and lesser component lacking glands, or predominantly lacking glands and lesser 
component of well-formed glands; group 5 (GS 9-10) to those with lack of gland formation or 
with necrosis, with or without poorly formed/fused/cribriform glands" (Epstein, Zelefsky et al. 
2016).  
There are several different types of treatment options available for PCa patients, 
depending on a system of risk stratification (that takes into account the PSA level, rectal 
exam finding, histological grade of the tumour, Gleason scoring) in addition to patient’s age, 
comorbidities and patient preference. The staging system that is used to date is the TNM 
(tumour, nodes, metastasis) system by the American Joint Committee on Cancer (AJCC). It 
classifies the tumour from grade I to IV, but also sub-categorises it, dependent on whether 
the lymph nodes are affected, the extent and also the presence of metastasis. Treatment 
options are based on this staging system (Edge, Byrd et al. 2010). Some men with localised 
PCa are candidates for deferred management. Active surveillance is an emerging and 
increasingly used option. This is mainly used to reduce overtreatment in patients with 
clinically confined low-risk PCa. However, radical prostatectomy, brachytherapy and 
radiotherapy are currently the treatment options available with curative intent for localised 
PCa. Once the tumour has progressed locally, within the prostate microenvironment, a 
routine treatment method is radiotherapy or watchful waiting. This option differs from active 
surveillance, as in watchful waiting the treatment is deferred till symptoms develop and 
when they do, the treatment is symptomatic control. If the tumour locally advances, 
hormone therapy could be additionally introduced to the patient in combination with 
radiotherapy. Hormone therapy alone could be suggested only if the cancer has spread to 
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another part of the body (metastatic disease). It works by blocking androgen receptors 
(gonadal and adrenal) that complement testosterone. The PCa growth is dependent on 
androgens as it had been shown that mice deprived of androgens, showed  a regression of 
their prostate tumours (Heinlein and Chang 2002). Androgen receptor signalling regulates 
the growth and development of the prostate and maintains prostate homeostasis (Heinlein 
and Chang 2002). However, if the anti-androgen therapy, followed by luteinizing hormone-
releasing hormone (LHRH) analogue monotherapy or combination of the two, becomes 
ineffective and the PSA keeps rising with the tumour becoming castrate resistant, then 
chemotherapy is considered as the next line of  treatment (Mottet 2015).  
  
All of these current treatments have considerable side effects: Surgery can render patients 
incontinent and/or impotent, while radiotherapy and chemotherapies could additionally 
cause fatigue, hair loss, nausea, neutropenia and anaemia, due to low numbers of white and 
red blood cells,  and can destroy normal tissue as well as cancer cells (Dearnaley, Khoo et al. 
1999). Due to the unpleasant side effects of these therapies, immunotherapy of PCa has 
been put forward as an alternative modality. Unfortunately, immunotherapy is introduced to 
the patient, once the cancer has metastasized and the patient has already undergone 
hormone therapy and chemotherapy, therefore the immune system is exhausted. This 
creates a great need for the development of novel therapies, which will offer a more 
personalised and tailored approach to patients who are refractory to the other available 
types of treatments.  
 
1.2 Immunity and cancer  
Cancer progresses by a combination of the ability of the cancer cell to transition and acquire 
mesenchymal properties and ability to metastasize, in addition to the failure of the body’s 
biological mechanisms to recognise and eliminate rogue cells. When the immune system fails 
to activate the anti-tumour immunity, cells begin to replicate uncontrollably, transforming, 
outgrowing and becoming neoplasms and eventually invasive tumours.  
 
1.2.1 The concept of immunoediting 
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Paul Ehrlich introduced the idea of immunotherapy more than 100 years ago, by 
suggesting that the immune system can attack transformed cells, such as tumour cells 
(Ehrlich 1906). It was believed that the host and tumour interactions are manipulated to 
favour targeting and the elimination of the tumour cells by the host immune cells, without 
harm to normal tissue.  
Since then, the concept of cancer immunoediting has become a central concept. This entails 
three main phases; elimination, equilibrium and escape.  
 
During the elimination phase, the immune system recognises the tumour cells and destroys 
them through innate and adaptive immune mechanisms. Initially innate immune cells like 
macrophages recognise the tumour cells and carry out limited killing. However as the tumour 
grows, stromal remodelling occurs and inflammatory cytokines are secreted by the 
surrounding macrophages, stromal and tumour cells leading to the recruitment of other 
innate immune effector cells such as Natural Killer (NK) cells and Dendritic Cells (DC) which 
attack the tumour cells. The DCs, which are a type of Antigen Presenting Cells (APCs), present 
the tumour antigens to CD4+ and CD8+ T cells in the context of MHC class II and class I 
molecules, respectively, and consequently the CD8+ T cells move to the tumour site to target 
and kill the tumour cells (Dunn, Old et al. 2004, Inoue, Yamazaki et al. 2006). However, the 
elimination phase creates a poorly immunogenic environment, due to the induction of new 
tumour variants that are resistant to immune effector cells, therefore an equilibrium phase is 
reached. This phase could occur over many years, where there is a balance between the new 
tumour cells that arise and the immune system trying to destroy them. Eventually, the 
tumour cells develop enough mutations, conferring resistance to the immune system’s 
‘attack’ which allows tumour evasion and an escape phase is established (Dunn, Koebel et al. 
2006). At that point tumour cells proliferate uncontrollably, resulting in the development of 





Figure 1.2: Illustration of the cancer immunoediting processes. At the beginning of the immunoediting 
process, the immune system cells eliminate the tumour cells, however tumour cell variants may 
become resistant to immune cell targeting and may start proliferating uncontrollably due to selection 





1.2.2 Types of immune effector cells involved in the anti-tumour immune 
response 
There are several immune effector cells of both the innate and of the adaptive immune 
system. These effector cells are thought to be able to recognise cancer cells as foreign and 
destroy them. These include NK cells, NKT cells, γδ T cells, CD8 T helper cells and DCs.  
 1.2.2.1. NK and NKT cells  
NK cells are considered part of the innate immune system, and comprise 2-18% of 
human peripheral blood lymphocytes (Vivier, Tomasello et al. 2008). They are largely found in 
the spleen and in lymph nodes (Witte, Wordelmann et al. 1990). They were discovered in the 
1970s and were  described as large granular lymphocytes (Cerwenka and Lanier 2001).They 
are the first  line of defence against an infection or a pathogen, capable of killing cells 
infected with viruses. In addition NK cells are able to kill mutated cells or tumour cells; it has 
been shown that NK cells are capable of killing virus- induced leukaemia cells and they are 
able to achieve this killing without the need of prior sensitisation to the target cells (Kiessling, 
Klein et al. 1975, Herberman and Ortaldo 1981, Lanier 2005).  
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It is important that NK cells are able to distinguish between healthy, stressed and 
transformed cells, so they have developed several mechanisms by which they recognise 
healthy cells that should not be targeted and those that should be attacked. These 
mechanisms form the basis of NK cell activation (Lanier 2005). They are activated either via 
their receptors, by which they can lyse cells without prior antigen stimulation, or via 
antibody- dependent cellular cytotoxicity (ADCC), which is exerted upon binding of the 
FcγRIIIα (CD16), expressed by NK cells, to the Fc part of the antibody-coated target cells 
causing the phosphorylation of immune tyrosine-based activating motifs (ITAM). This leads to 
binding to tyrosine kinases ZAP-70 and Syk, activation of PI3K, NF-κB and ERK pathways, and 
cytokine secretion. This ultimately leads to lysis of target cells (Seidel, Schlegel et al. 2013, 
Wang, Erbe et al. 2015). CD16 has been also shown to play a direct role in NK cell 
cytotoxicity, independent of antibody binding (Mandelboim, Malik et al. 1999) and it has 
been reported that CD16dim CD56bright NK cells have increased cytokine production, but it is 
the CD16bright CD56dim populations that show an increased cytotoxic capacity (Vivier, 
Tomasello et al. 2008). NK cells can be primed in a DC-dependent way, in response to various 
cytokines, such as IL-2, type I IFNs and IL-15 (Walzer, Dalod et al. 2005).  
 
NK cells are regulated and have the ability to distinguish transformed cells from 
healthy cells, by two recognition pathway mechanisms called ‘missing-self’ and ‘induced-self’ 
(Karre 2002, Bryceson, March et al. 2006). The ‘missing-self’ mechanism is led by the lack of 
protection of self-cells and involves the recognition of an altered stress-induced glycoprotein 
cell surface composition, together with an ‘induced-self’ MHC molecule expression change, 
through an array of inhibitory and activatory receptors that are expressed on their cell 
surface.  
The inhibitory receptors (iNKR) that they express, recognise molecules of the major 
histocompatibility complex- I (MHC-I); for humans these receptors are called killer 
immunoglobulin-like (KIR) and in mice Ly46; additionally they both express a heterodimer of 
CD94-NKG2A.  As tumour cells express low levels of MHC-I molecules, they often escape this 
inhibitory signalling by NK cells, so in order for NK cells to be activated, they rely on the 
stimulatory signals by the activatory NK receptors (aNKR), which recognise stress-induced 
signals on the surface of the target cells (Bottino, Castriconi et al. 2005). Notable examples 
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are NKG2D and DNAM-1 as well as the natural cytotoxicity receptors NKp30, NKp44 and 
NKp46. The NK receptors and ligands will be further discussed on section 1.2.3.  
 
Cell killing is mediated through the release of cytotoxic granules containing perforin and 
granzyme (Voskoboinik, Smyth et al. 2006, Topham and Hewitt 2009), the ligation of death 
receptors such as TRAIL and Fas Ligand and through the release of a number of pro-
inflammatory cytokines and chemokines, such as IFNγ, TNFα, GM-CSF, CCL2 and CCL5 which 
are involved in the activation of the adaptive immune system cell and which will further 
attack the tumour cells (Yokoyama, Kim et al. 2004, Zwirner and Domaica 2010, Bernardini, 
Gismondi et al. 2012, Romee, Leong et al. 2014). Hence, it is believed that NK cells have also 
immunomodulatory properties, as they can positively or negatively influence anti-cancer 
responses by DCs and T cells (Sungur and Murphy 2014).  
 
The important role of NK cells in immunosurveillance was supported by a study in mice 
where it was shown that RAG-/- mice (lacking adaptive immunity) had decreased tumour 
incidence and formation, compared to RAG-/- x γc-/- (lacking all lymphocytes, both of the 
innate and adaptive immunity) (O'Sullivan, Saddawi-Konefka et al. 2012). Furthermore, 
Guerra et al. 2008 showed that in a TRAMP mouse model, NKG2D-dificient mice (Klrk1-/-) 
were three times more susceptible than wild-type mice to developing highly malignant 
tumours, demonstrating the important role of the NK-NKG2D interaction in 
immunosurveillance (Guerra, Tan et al. 2008). Figure 1.3 is adapted by (Pahl and Cerwenka 












Figure 1.3: NK cell cytotoxicity regulation during cancer immunosurveillance and cancer escape. NK cells 
interact with cancer cells via the inhibitory (in red) and the activatory (in green) receptors and their 
corresponding ligands on tumour cells. Target cell apoptosis is induced via perforin and granzyme 
production, through the Fas Ligand and TRAIL expressed on NK cells and via CD16 antibody-
dependent cellular cytotoxicity (ADCC). The involvement of cytokines (e.g. IL-18, IL-2, IL-15) produced 
by immune effector cells stimulate the NK cell cytotoxicity. TGFβ, IL-10, prostaglandin E2 (PGE2), 
vascular endothelial growth factor (VEGF), nitric oxide species (NOS) and reactive oxygen species 
(ROS), produced by immunosuppressive cell populations (e.g. Treg, Macrophages) promote the tumor 
escape from NK cell surveillance and the immunosuppression in the cancer microenvironment. 






NKT cells comprise about 1% of circulating lymphocytes and they differ from NK cells 
because of the antigen-specific T cell receptor (TCR) that they express on their surface. NKT 
cells express the CD56 marker as NK cells, and also CD3 as T cells (Godfrey, MacDonald et al. 
2004).  
NKT cells are thought to create a bridge between the innate and the adaptive immunity and 
they are classified into two categories –Type I and Type II- dependent on their role in 
immunity. Type I NKT cells express an invariant Vα14Jα18 TCR whereas type II express 
variable TCRs (Cardell, Tangri et al. 1995).  Both types produce Th1 and Th2 cytokines, IFNγ 
and IL-4 respectively, upon stimulation with the CD1d antigen presentation. Type I NKT cells 
have a protective role dependent on their ability to produce IFNγ, however they don’t act 
directly on tumour cells, although they are able to lyse cells. Rather, Type II NKT cells act 
through their effects on other types of immune cells such as NK and CD8 T cells, or DCs, 
which make IL-12 thus contributing to their anti-tumour effect (Toura, Kawano et al. 1999, 
Metelitsa, Naidenko et al. 2001). Quite paradoxically, type II NKT cells are thought to be 
involved in the suppression of the anti-tumour response (O'Konek, Kato et al. 2013).  
 
1.2.2.2 CD8 T cells  
Cytotoxic T cells (CD8 T cells), an adaptive immune cell type, become activated and 
induce cytolysis and IFNγ production, upon their encounter with aberrant antigens bound to 
MHC Class I molecules, presented by the Antigen Presenting Cell (APC).  
Many immunotherapeutic strategies are designed to stimulate and enhance the CD8 T cell 
activity by targeting and overcoming the peripheral tolerance, which exists to protect healthy 
tissues from immune mediated attack, since tumours also express self-antigens characteristic 
of the healthy tissues from which they are derived.  
 
It has been suggested that intraprostatic CD8+ T cells are non-functional, or unable to 
upregulate activation markers such as CD69 or CD137 in response to external stimuli 
(PMA/ionomycin) (Bronte, Kasic et al. 2005). Furthermore, the secretion of TGFβ and IL-10 by 
tumour cells has been shown to confer a regulatory CD8 effector T cell phenotype within the 
PCa microenvironment whereby FoxP3 may be expressed by these cells, enabling them to 
suppress any CD8 effector cells and therefore their cytotoxic activity towards tumour cells; 
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this may be one of the mechanisms that tumour cells escape the immune response (Shafer-
Weaver, Anderson et al. 2009).  
 
1.2.2.3 Gamma delta (γδ) T cells  
γδ T cells are a small proportion of circulating T lymphocytes (1-5%) , that express 
antigen receptors that undergo VDJ (variable-diversity-joining) recombination creating a 
repertoire diversity in T cells. They are mostly abundant in mucosal sites and they contribute 
to immune response, infection and tissue damage, by producing pro-inflammatory cytokines 
such as IFNγ and IL-17 as well as anti-inflammatory cytokines like TGFβ and IL-10 (Rincon-
Orozco, Kunzmann et al. 2005, Kuhl, Pawlowski et al. 2009, Rei, Goncalves-Sousa et al. 2014). 
They have been reported to have a protective role in B cell lymphomas and in PCa, due to the 
IFNγ production, however, it has been shown that they can also promote tumour growth due 
to the IL-17 production (Rei, Pennington et al. 2015).  
 
1.2.2.4 Macrophages and Dendritic cells (DCs) 
Macrophages and DCs are innate immune cells that are activated through cellular 
receptors known as pattern recognition receptors (PRRs). These are activated through 
pathogen-associated molecular patterns (PAMPs), which are present on a variety of 
microorganisms, such as bacteria, fungi and viruses, but are not present on tumour cells. So 
PRRs do not become activated to attack cells expressing tumour-associated antigens (TAA) 
and as a consequence the innate immune cells fail to elicit a response (Berke 1994).   
DCs are bone marrow-derived cells that provide a link between innate and adaptive 
immunity, as they control both tolerance and immune responses (Reis e Sousa 2001). 
Immature DCs recognise antigens either a) by phagocytosis, using complement receptors and 
Fc receptors and C-type lectins, or b) by micropinocytosis, or c) by using signalling receptors, 
such as TLRs, that recognise PAMPs, and respond by secreting cytokines (eg. IL-12, IFNα). It is 
believed that unlike other APCs (e.g. Macrophages, B cells), their only function is to stimulate 
the adaptive immunity by presenting the foreign antigens in a complex of peptide-MHC I or II 
28 
 
molecules to naïve CD8 or CD4 T cells respectively, which activates the T cells, especially the 
cytotoxic CD8+ T cells to act against the target cells (Palucka and Banchereau 2012).   
 
1.2.3 Mechanism of tumour cell killing by NK cells: NK receptors and ligands 
NK cells have developed mechanisms that aid their activation in order to effectively 
distinguish between healthy and tumour cells and eventually cause target lysis. They do that 
either via ADCC or via the interaction between the NK receptors (NKRs) and their 
corresponding ligands on tumour cells.  
 
The human KIR inhibitory receptor genes demonstrate extensive polymorphism and encode 
for type I transmembrane glycoproteins that evolved from the immunoglobulin (Ig) 
superfamily, having two or three Ig-like domains (designated as KIR2D- or KIR3D-) in the 
extracellular region, which have been designated as D0, D1 or D2. Within the KIR subfamilies 
heterogeneity is observed in terms of the cytoplasmic domain, which could be either long 
(designated as KIR2DL- or KIR3DL-), characterised by two or three immunoreceptor tyrosine-
based inhibitory motifs (ITIM) or short (designated as KIR2DS- or KIR3DS-), lacking ITIMs 
(Colonna and Samaridis 1995).  
ITIMs are found in the cytoplasmic domains of all inhibitory NKRs, with a consensus sequence 
Ile/Val/Leu/Ser-x-Tyr-x-x-Leu/Val, where x denotes any amino acid. Upon ligand binding, 
tyrosine phosphorylation occurs by a src kinase that leads to an NK cytotoxicity or cytokine 
production, via the recruitment of tyrosine-specific phosphatases SHP1 or SHP2 or the 
phospholipid-specific phosphatase SHIP (Muta, Kurosaki et al. 1994, Binstadt, Brumbaugh et 
al. 1996).  
KIRs recognise ligands of the HLA protein family (A, B or C) and can discriminate between 
different peptides presented by them (Colonna, Spies et al. 1992) (see table 1.1). However, 
the biological relevance is still unclear, as these KIR receptors do not distinguish between self 
and non-self peptides.  
The activatory receptors use adapter molecules containing an immunoreceptor 
tyrosine-based activation motif (ITAM) to provide signalling function. These ITAM motifs have 
a consensus sequence of Asp/Glu-x-x-Tyr-x-x-Leu/Ile x6-8 Tyr xx Leu/Ile, where x represents 
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any amino acid, with 6 to 8 amino acids between tyrosine (Tyr) and Leucine/Isoleucine 
(Leu/Ile). Upon phosphorylation of the ITAM, the tyrosine kinases Syk and Zap70 (zeta chain 
of T cell receptor associated protein kinase 70) are recruited and activate downstream events 
that lead to NK receptor signal transduction (Reth 1989). 
One of the most well investigated activatory receptors is NKG2D, member of the 
NKG2 family of genes, which however has very little homology to the other member of the 
family. It is a type II transmembrane-anchored glycoprotein, expressed in humans by NK cells 
as well as by CD8+ T cells. NKG2D lacks an ITAM motif, therefore adapter molecules like 
Dap10 are needed for signal transduction (via the PI3K pathway) that will trigger cytotoxicity 
(Wu, Song et al. 1999).  
 NKG2D recognises ligands of the MHC Class I family and in humans these are MICA and 
MICB, induced upon cellular stress, and the UL-16 Binding Proteins 1-4 (ULBP1-4) (Bauer, 
Groh et al. 1999). Tumour cells exploit these ligands by shedding them from the cell surface, 
in order to evade the immune system and escape the immune surveillance of NK cells 
(Waldhauer and Steinle 2006, Waldhauer, Goehlsdorf et al. 2008).  
 Another family of activatory receptors is that of the Natural Cytotoxicity Receptors 
(NCRs). There are three members of that family, NCR1 (NKp46), NCR2 (NKp44) and NCR3 
(NKp30), which are exclusively expressed on NK cells, but NKp44 is expressed only by 
activated NK cells. Phosphorylation of their ITAM motifs activates signalling pathways that 
leads to cytotoxicity and cytokine degranulation (Sivori, Vitale et al. 1997, Vitale, Bottino et al. 
1998, Pende, Parolini et al. 1999). To date only a few of their ligands have been identified. 
Table 1.1 shows a selected panel of receptors and their corresponding ligands that were 












Receptor Ligand Function 
Killer Immunoglobulin-like receptors (KIRs) 
KIR2DL1 HLA-C, C2 Inhibitory 
KIR2DL2/3 HLA-C, C2 Inhibitory 
KIR3DL1 HLA-A, HLA-B Bw4 Inhibitory 
Cytotoxicity receptors 
NKp30 Unknown; B7-H6 homolog? Activatory 
NKp44 
NKp44L- isoform of the mixed-lineage 
leukemia-5 (MML5) protein 
Activatory 
NKp46 Unknown Activatory 
NKG2D MICA, MICB, ULBP family proteins Activatory 
DNAM-1 Nectin-2 Activatory 
 
Table 1.1: A selected panel of activatory and inhibitory NKRs and their corresponding ligands that are 

















1.3 Immunosuppression in the PCa microenvironment 
1.3.1 Suppressive immune cell populations and proteins expressed within the 
cancerous prostate and associated stroma 
In recent years, there has been increasing evidence that immunosuppression 
associated with a lack of activity of immune effector cells such as NK cells contributes 
towards progression of PCa (Koo, Shim et al. 2013). The PCa microenvironment is highly 
immunosuppressive and it is suggested that although immune cells (e.g. NK and CD8 Tcells) 
infiltrate the cancerous prostate, they are rendered anergic or even regulatory  (Shafer-
Weaver, Anderson et al. 2009). 
 
The immune cell types that infiltrate the prostate have been demonstrated in several 
studies. These include the IFNγ-producing Th1 cells, IL-4-producing Th2 cells and IL-17-
producing Th17 cells, as well as CD4+, CD8+ and FoxP3+ Treg cells (Kiniwa, Miyahara et al. 
2007, Sfanos, Bruno et al. 2008). In a separate study by Hadaschik et al. (2012), T cells 
isolated from peripheral blood of PCa patients showed an increased response rate to TAA 
compared to those isolated from benign prostatic hyperplasia (BPH) patients or healthy 
donors. Furthermore, they showed an increased T cell response when Treg cells were 
depleted, demonstrating a suppressive phenotype of these Treg cells towards the immune 
response in PCa patients (Hadaschik, Su et al. 2012).  Using the TRAMP mouse model of PCa, 
it was observed that although T-antigen specific T and B cells were capable of recognising 
tumour cells, the cytotoxic T lymphocytes were unable to kill them due to the 
immunosuppression caused in the tumour microenvironment (Willimsky, Czeh et al. 2008).  
 
When trying to understand the mechanisms of immunosuppression in the PCa 
microenvironment, a number of immunosuppressive factors in the form of either secreted or 
cell surface proteins, growth factors or regulatory immune cells were shown to contribute. 
In the study by Kiniwa et al. (2007) that was mentioned earlier, an increased number of CD4+ 
CD25+ FoxP3+ Treg cells in the prostate tumours was observed, however in addition to these, 
another rarer population of CD8+ CD25+ FoxP3+ seemed to enter the cancerous prostate and 
suppress both the T cell proliferation and activity and NK cell function (Kiniwa, Miyahara et al. 
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2007). In further studies, the rare population of T suppressor cells (CD8+ CD25+ FoxP3+ ) was 
found to mediate and suppress T- effector cell responses to TAA, through CTLA-4 (Cytotoxic T 
Lymphocyte Antigen-4) expression and IL-35; CTLA-4 blockade relieved the suppressive 
phenotype (Olson, Jankowska-Gan et al. 2012, Arruvito, Payaslian et al. 2014). Yu et al. 2012, 
also demonstrated that CTLA-4 and PD-L1 (Programmed Death Ligand-1) blockade ‘break’ the 
Treg suppression of IL-15-induced CTL immunity in TRAMP tumours in mice (Yu, Steel et al. 
2012).  
 
Regarding NK cells, which are the main focus in this study, a defect in their cytotoxic activity 
as PCa progresses to the metastatic stage has been observed (Koo, Shim et al. 2013, Liu, Lu et 
al. 2013), which is attributed to the presence of cancerous cells in the circulation (Kastelan, 
Kraljic et al. 1992).  Another type of cells that infiltrate the PCa environment and have a 
suppressive function against NK cells, T cells and DCs, are the immature myeloid suppressor 
cells (Almand, Clark et al. 2001, Gabrilovich, Ostrand-Rosenberg et al. 2012). These are either 
recruited by tumour cells or they are formed from active non-suppressive cell populations 
through cytokine secretion by tumour or stromal tissue (Elhage, Galustian et al. 2012).  
Moreover, Treg cells seemed to suppress the NK cell function in a TGFβ dependent manner, 
through the downregulation of NKG2D both in vitro and in vivo in a study by Ghiringelli et al. 
(2005); blockade of Treg cells ameliorated the NK cell cytotoxic activity (Ghiringhelli, Menard 
et al. 2005).  
TGFβ is a growth factor that has been implicated in the tumour immunosuppression 
in PCa.  Many tumours produce high levels of TGFβ, hence its blockade or impairment could 
enhance the tumour rejection by the immune system. A suggested mechanism by which 
tumour cells evade the immune system is through the conversion of CD4+ T cells into Treg 
cells in the tumour sites due to the TGFβ that is produced in the tumour cells (Liu, Wong et 
al. 2007). 
Together with IL-10, they are both secreted by fibroblasts and cells surrounding the PCa 
environment, promoting angiogenesis and inhibition of the CD4 and CD8 T cell proliferation 
(Ahuja, Paliogianni et al. 1993, Arteaga, Hurd et al. 1993).  
Two separate studies by Zhang et al. (2006) and Shafer-Weaver et al. (2009) showed that 
TGFβ signalling blockade induced CTL tumour infiltration in mice, where CD8 T cells specific 
for the tumour were adoptively transferred (Zhang, Yang et al. 2006, Shafer-Weaver, 
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Anderson et al. 2009). However, other studies have suggested that long-term TGFβ blockade 
could result in autoimmunity, hence a fine balance between tumour immunity and 
autoimmunity should be maintained.  
 
A number of cell surface and secreted proteins are expressed by cells of the tumour 
microenvironment which can inhibit the immune response by effector immune cells: these 
include complement regulatory proteins, such as CD46, CD59, CD55 and CD97 which are 
highly expressed in tumour cell populations (Loberg, Wojno et al. 2005) and inhibitory ligands 
of the MHC family that inactivate NK, CD8 and dendritic cells (Lanier and Phillips 1996); also, 
a number of cytokines and chemokines that are thought to be secreted by tumour stromal 
cells (in addition to their normal production by haemopoeitic cells). Instead of activating the 
infiltrating immune cells, they inhibit them through their aberrant structures, locations and 
presentation on the cells. In a study by Su et al. (2010) it was reported that tumour-derived 
fibroblasts secrete MCP-1 (CCL2) and RANTES (CCL5) that recruit Th17 cells into the tumour 
sites, and by the secretion of pro-inflammatory cytokines (e.g. IL-1, IL-6, IL-23 and TGFβ), 
Th17 cells undergo differentiation and expansion, which suppresses further the tumour 
microenvironment (Su, Ye et al. 2010).  
Another factor that was implicated in the immunosuppressive activity is the prostaglandins of 
the series E (PGE), derived from the seminal plasma. It has been reported that that they 
suppress the lymphocyte and NK cell proliferation and activation. Additionally they are 
involved in the antibody class switching, as well as in the polarization of Th1 cells to a Th2 
pattern (Kelly 1995). 
So it is suggested that while the immune system is able to recognise and attack the tumour 
cells, the immunosuppression in the cancerous microenvironment that is caused by various 
factors, allows the tumour cells to escape and suppress the immune responses directed 








1.3.2 Immunological checkpoints  
The immunological checkpoints represent a balance that is kept between co-
stimulatory and inhibitory signals in the immune system, which under normal conditions are 
important in maintaining homeostasis and self-tolerance, to prevent autoimmunity and to 
protect tissues from damage when the immune system responds to a foreign antigen. The 
interactions between ligands and receptors are often manipulated by tumours, as a 
mechanism for tumour cell escape from the immune system: T cells are capable of directly 
recognizing and killing target cells (CTLs) and of orchestrating immune responses from both 
the innate and adaptive immunity, hence agonists of co-stimulatory receptors or antagonists 
of inhibitory signals have been the main focus of the design of novel cancer 
immunotherapeutics. Figure 1.4 shows a variety of receptor-ligand interactions between T 






Figure 1.4: Pairs of co-stimulatory- inhibitory receptors and their corresponding ligands. The T cell 
response to a foreign antigen is dependent on the receptor-ligand interactions between T cells and 










These immune checkpoints were found to contribute to  the immunosuppression in 
the prostate gland and since then they have become targets of immunotherapy (Pardoll 
2012). 
CTLA-4 is an inhibitory receptor, expressed on activated CD4+ and CD8+ T cells, 
binding to B7-1 (CD80) and B7-2 (CD86) co-stimulatory molecules on APCs; it was found that 
it is also expressed on Treg cells, thus contributing to immunosuppression (Wing, Yamaguchi 
et al. 2011). Furthermore, its blockade has emerged as an important immunological adjuvant 
for DNA vaccines in cancer immunotherapy (Gregor, Wolchok et al. 2004). 
 
PD-1 (Programmed Death-1) is a co-inhibitory receptor (the other receptor is PD-2), 
also expressed on activated CD4+ and CD8+ T cells, B and NK cells and even monocytes post 
cytokine stimulation, which limit the immune cells’ target lysis. PD-1 binds to the PD-L1 ligand 
on APCs and their interaction leads to downregulated T cell proliferation due to the 
inactivation of effector molecules such as Zap70 (zeta chain of T cell receptor associated 
protein kinase 70) (Agata, Kawasaki et al. 1996). Furthermore it is shown that this interaction 
promotes the CD4 T cell conversion to Treg cells, thus preventing autoimmunity (Dong, 
Strome et al. 2002, Blank, Brown et al. 2004). It has been reported that PD-1 enhances 
tumour cell proliferation and tumour growth after ligand binding, PD-L1, which is over-
expressed in cancer cells, stromal cells and TILs (Zou and Chen 2008, Topalian, Drake et al. 
2012). PD-1, has been found to be expressed at lower levels in cells derived from PCa 
patients, unlike the cells from healthy donors, suggesting that the lymphocytes involved in 
the PCa eradication are inhibited or exhausted (Freeman, Long et al. 2000, Ebelt, Babaryka et 
al. 2009). Moreover, increased numbers of FoxP3+, PD-1+ and PD-L1+ lymphocytes were 
detected in PCa lesions, which suppressed the anti-tumour immunity (Ebelt, Babaryka et al. 
2009). Castrate-resistant PCa (CRPC) patients, that were refractory to anti-androgen 
enzalutamide treatment, showed an increased frequency of PD-L1+ DCs (Bishop, Sio et al. 
2015). One study reported the stromal growth factors CCL2, IL-6 and TGFβ released by 
stromal myofibroblasts in the PCa microenvironment, induced monocyte differentiation into 
a suppressive DC phenotype (CD14+, PD-L1+ DCs), which further contributed in the 




B7-H3 and B7-H4 are type I transmembrane proteins, with unknown receptor to date, 
that are expressed on activated APCs and have been implicated in immunomodulatory 
processes in PCa, and enhancing the tumour progression in various cancer types such as 
gastric, prostate and renal cell carcinoma (Zang, Thompson et al. 2007, Arigami, Uenosono et 
al. 2010, Qian, Yao et al. 2010). Overexpression of B7-H3 has been associated with increased 
frequency of TILs, increased tumour growth and progression to the metastasis stage in 
various cancer types, such as breast, hypopharyngeal squamous cell carcinoma and gastric 
carcinoma (Wu, Jiang et al. 2006, Arigami, Narita et al. 2010, Katayama, Takahara et al. 2011). 
In vitro experiments with melanoma cell lines showed that silencing B7-H3 inhibited 
metastasis, by downregulating MMP-2 (matrix metallopeptidase-2), involved in tumour cell 
migration, invasion and metastasis, with a concomitant increase in TIMP-1 and TIMP-2 (TIMP 
metallopeptidase inhibitors 1 and 2), involved in MMPs inhibition. It also downregulated 
STAT-3 phosphorylation levels, involved in metastasis and promoting cell signalling, and 
finally downregulated IL-8 which promotes melanoma metastasis (Tekle, Nygren et al. 2012).  
In regards to PCa, molecules of the B7 family were found to be present on 93-99% of PCa 
cells correlating with a poor disease prognosis in patients (Roth, Sheinin et al. 2007, Zang and 
Allison 2007). B7-H3 was additionally associated with higher Gleason score, higher Ki67 
proliferation marker and larger tumour volume and found to be expressed in bone metastasis 
and hormone-resistant PCa specimens (Roth, Sheinin et al. 2007, Chavin, Sheinin et al. 2009, 
Liu, Vlatkovic et al. 2012). Interestingly, a recent in vivo study in TRAMP mice directly 
associated lack of B7-H3 and not of B7-H4 with an increased Treg cell accumulation in the 
PCa microenvironment, suggesting that the presence of B7-H3 has an inhibitory mechanism 
towards the FoxP3+ Treg expression (Kreymborg, Haak et al. 2015).  
 
TIM3 (T cell immunoglobulin domain and mucin domain-containing molecule 3), is 
another immune checkpoint receptor that has recently been reported to cause immune 
suppression in cancer. It is expressed exclusively on Th1 CD4+ T cells and upon binding to its 
ligand, Galectin-9, it is thought to inhibit Th1 and Th17 responses (Sakuishi, Jayaraman et al. 
2011). In preclinical models of solid and haematological malignancies, a suppressive 
population of CD8+ T cells that co-expressed TIM3 and PD-1, exhibited defects in proliferation 
and cytokine production, enhancing tumour growth (Sakuishi, Apetoh et al. 2010). In PCa 
specimens, TIM3 has been correlated with higher Gleason score, poor prognosis of disease 
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and disease progression (Piao, Jin et al. 2014). TIM3 blockade on PCa tumour models 
(TRAMP-C1 prostate carcinoma) resulted in tumour regression, however blockade of both 
TIM3 and PD-1 resulted in an even greater tumour regression, suggesting that utilizing 
combinatorial blockade of immune checkpoint inhibitors could enhance the anti-tumour 
immunity.  
 
1.4 Cancer immunotherapeutic strategies 
The manipulation of the host and tumour cell interactions in order to stimulate the 
immune cells to recognise and target the cancer cells, is the primary aim of the current 
immunotherapeutic approaches that are used in cancer treatment. Various 
immunotherapeutic modalities exist for the treatment of several cancers; these include 
protein-based immunotherapies, antibody-based, cell-based and through the non-specific 
activation of the immune system (Figure 1.5).  
 
 






1.4.1 The use of cytokines in protein-based immunotherapies  
Non-cell based immunotherapies include the use of growth factors (e.g. GM-CSF), or 
the use of cytokines; these bind to cell surface receptors, stimulating the immune cell growth 
and activation. Cytokine treatment aims to stimulate the immune system cells to trigger a 
response, either by increasing the immune cell proliferation with a concomitant activated 
cytotoxicity towards the cancer cells, or by cytokine production which increases the immune 
reactivity (Smyth, Cretney et al. 2004). Notable examples of cytokines that are used in cancer 
treatment, are IL-2 and IFNα, which were approved by the Food and Drug Administration 
(FDA) in 1992 and 2011 respectively, for their use in metastatic melanoma treatment, and in 
1998 and 2009 respectively, for their use in renal cell carcinoma (RCC), based on their 
pleiotropic effects on immune cells (Belardelli, Ferrantini et al. 2002, Gaffen and Liu 2004).  
IL-2 has myriads biological effects on immune cells, including the expansion of CD4+ 
and CD8+ T cells, augmenting their cytokine production and hence their cytolytic activity. 
Additionally, it stimulates tumour-infiltrating lymphocytes to target and attack the cancer 
cells (Gaffen and Liu 2004).  
270 patients with metastatic melanoma, treated with IL-2 and enrolled into clinical trials 
between 1985 and 1993, were reviewed; 17% of patients showed complete response 
whereas 10% showed partial response. It was concluded that IL-2 should be considered as a 
therapeutic option for metastatic melanoma, as no responder showed further disease 
progression (Atkins, Kunkel et al. 2000).  
In the case of RCC, 259 patients who were treated with high doses of IL-2, were reviewed for 
the period between 1986 and 2006; the complete responders were 23%, whereas the partial 
responders were 30%. Only 4 complete responders developed disease recurrence, but all the 
partial responders experienced disease recurrence. IL-2 caused toxicities in many patients, 
but only 2 of them died of these. Overall, it was concluded that high dose of IL-2 produced 
tumour regression and despite the toxicities associated with it, it should still be considered as 
a treatment for patients with RCC (Belldegrun, Klatte et al. 2008, Klapper, Downey et al. 
2008). In a separate study, it was shown that localized injection of IL-2 into a skin lesion can 
promote systemic activation of anti-tumour immunity to clear distant tumours (Johnson, Lum 
et al. 2008). Furthermore, Schwartzentruber et al (2011) showed that the administration of a 
synthetic peptide vaccine together with IL-2 prolonged a progression–free and overall 
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survival of melanoma patients, unlike IL-2 monotherapy (Schwartzentruber, Lawson et al. 
2011).  
IFNα also enhances the cytolytic activity of lymphocytes as well as increasing the 
macrophage phagocytic activity and is considered as adjuvant therapy in patients with RCC 
and melanoma (Coppin, Porzsolt et al. 2005, Mocellin, Pasquali et al. 2010). Furthermore, 
combination of IL-2 and IFNα treatments increased the overall survival of RCC patients with 
lung metastases (Negrier, Escudier et al. 1998). 
IL-12 is a cytokine produced by APCs in response to an antigenic stimulus, promoting 
CD4+ T cell polarization to Th1, promotes anti-tumour responses and inhibits tumour derived 
Treg cells (Kilinc, Aulakh et al. 2006, Zhao, Zhao et al. 2012). It is another example of 
interleukins that showed some promising results in cancer treatment, as in the case of T cell 
lymphoma (Rook, Wood et al. 1999), non-Hodgkin’s B cell lymphoma (Younes, Pro et al. 
2004) and AIDS-associated Kaposi sarcoma (Little, Pluda et al. 2006). 
IL-15 is a pro-inflammatory cytokine that plays an important role in autoimmunity and 
inflammation. Its mRNA is expressed by a variety of tissues and cell types, including 
fibroblasts, keratinocytes, nerve cells, monocytes and macrophages (Anderson, Kumaki et al. 
1995). There is little evidence known indicating that IL-15 plays a direct role in the 
development of solid cancers (Lissoni, Rovelli et al. 1998); rather it may offer a protective role 
in the immunosurveillance during a tumour formation. There are several current ongoing 
clinical trials involving IL-15 for the treatment of various cancer types such as RCC, melanoma 
and acute myeloid leukemia (AML).  
IL-21 is a pleiotropic cytokine that bridges the innate and adaptive immunity; 
activated CD4+ T cells produce it, whereas upon cell activation, it expands the CD8+ T cells 
and aids their cytotoxic activities (Hinrichs, Spolski et al. 2008). Several preclinical studies 
have presented the anti-tumour effects of IL-21 in various in vivo tumour models, such as in 
the case of B16 melanoma and MethA fibrosarcoma, where IL-21 was used in a vaccine 
platform that provided 50% protection before, and 70% cure after tumour challenge of non-
immunogenic tumours (Ma, Whitters et al. 2003) . Furthermore, IL-21 was shown to promote 
immune protection to mice in a colon carcinoma model (Ugai, Shimozato et al. 2003).  
It is crucial to point out that these cytokines are used systemically and they can be 
extremely toxic, so they are only suitable for patients that are refractory to any other 
treatment (Fehniger, Cooper et al. 2002). Their localization to the cancerous lesion would 
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both increase their efficacy and lower their toxicity. Also when considering such agents for 
immunotherapies – it is vital to consider their actions at the site of the lesion where the 
immune system is most compromised. Many cytokines will have no effect when injected into 
this immunosuppressive environment based on the preliminary in vitro data described on 
chapter 3. 
 
1.4.2 Antibody-based immunotherapies  
Recent studies in cancer immunotherapy have focused on the concept of immune 
checkpoints and on the development of antibodies against immunological checkpoint 
proteins that are used either alone or in combination with other drugs. 
The first fully human FDA- approved monoclonal antibody was Ipilimumab, targeted 
against CTLA-4, for the treatment of metastatic melanoma. Long term follow-up of patients 
with metastatic melanoma that were treated with ipilimumab, showed an overall survival in 
19-36% of patients, with an up to 4 years life extension and manageable immune related 
adverse events (Hodi, O'Day et al. 2010, Prieto, Yang et al. 2012, Lebbe, Weber et al. 2014). 
Based on these results, ipilimumab is currently in trials for the treatment of non-small cell 
lung carcinoma, metastatic RCC and ovarian cancer (Tse, Collins et al. 2014, Garon 2015, 
Parekh and Rini 2015).   
In PCa in a phase I clinical trial involving CRPC patients, combination of ipilimumab with GM-
CSF induced an expansion of circulating CD25+ CD69+ CD8+ T cells as well as a decline in the 
PSA levels in 50% of patients that received the highest doses of anti-CTLA-4 antibody. 
Furthermore, one patient showed a partial response in visceral metastasis (Fong, Kwek et al. 
2009).  
Two phase III trials have been initiated; the first was investigating the effects of ipilimumab 
versus placebo in patients with metastatic CRPC that had progressed after docetaxel 
treatment, and the initial findings showed no significant difference between the two groups 
in terms of the overall survival benefit.  However, further subgroup analyses showed that 
ipilimumab offered a greater survival benefit (~6.9 months increased survival) to patients 
with specific baseline characteristics, such as alkaline phosphatase <1.5 times the upper limit 
of normal and haemoglobin >11.0g/dL (Kwon, Drake et al. 2014). The second clinical trial 
(NCT02279862) is investigating the safety and efficacy of different doses of ipilimumab in 
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patients with metastatic CRPC, with no prior chemotherapeutic agent administration. It is 
currently ongoing, hence there are no results available yet.  
Tremelimumab is another fully human monoclonal antibody against CTLA-4, which was 
investigated in phase I trials in PSA-recurrent PCa patients after surgery and/or radiation 
therapy, however no significant changes were observed in PSA doubling time shortly after 
completing the treatment (McNeel, Smith et al. 2012).  
 Two recently FDA-approved monoclonal antibodies targeted against PD-1 for the 
treatment of metastatic melanoma are Nivolumab and Pembrolizumab; the first is given in 
patients who are already treated with ipilimumab or serine/threonine protein kinase B-Raf 
(BRAF) inhibitor (Robert, Long et al. 2015, Weber, D'Angelo et al. 2015), whereas 
pembrolizumab is given in patients without prior ipilimumab treatment (Sullivan and Flaherty 
2015). In 2015, the FDA also approved nivolumab for the treatment of refractory squamous 
non-small cell lung carcinoma (Topalian, Hodi et al. 2012).  
No study to date has proven that nivolumab monotherapy is efficacious in PCa patients, 
however there are two currently ongoing clinical trials; the first one (NCT02601014) is testing 
combination therapy of ipilimumab with nivolumab in metastatic hormone-resistant PCa 
patients and the second (NCT02499835) is studying the combination of a DNA vaccine 
therapy with pembrolizumab in the treatment of patients with hormone-resistant PCa.  
 
 1.4.3 Non-specific immunotherapies  
Non-specific immunotherapies focus on widespread changes that will lead to the 
immune system activation, without the need of inducing responses to specific antigens. Such 
therapies include the use of mycobacteria, immune stimulatory agents such as CpG 
oligonucleotides, or enzyme inhibitors such as of indolamine-2,3-dioxygenase (IDO).  
CpG oligonucleotides activate innate effector cells and APCs via toll-like receptor signalling 
and additionally they are thought to suppress the activity of myeloid-derived suppressor cells 
(Shirota, Shirota et al. 2012).  
IDO has various immunosuppressive effects in the tumour microenvironment as it is over-
expressed in the tumour-infiltrating immune lymphocytes. It induces Treg cell expansion in 
the tumour microenvironment and it inhibits the NK and T cell proliferation as well as their 
activation (Munn and Mellor 2007). Hence it is crucial to inhibit the actions of such an agent 
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and indeed there have been several IDO inhibitors developed and tested, such as 1-Methyl-
D-tryptophan. The latter has been tested in synergy with chemotherapeutic drugs (e.g. 
Doxorubicin, cyclophosphamide) in vivo in RAG-1 deficient hosts (lacking T and B cells), 
inducing antitumor immune responses (Hou, Muller et al. 2007). 
 
1.4.4 Cell-based immunotherapies and vaccines 
Cell based immunotherapies have produced less beneficial survival outcomes in 
comparison to passive immunotherapies (e.g. Antibody-based) overall, however, in the past 
few years that trend has changed. That is due to our better understanding of how the tumour 
cells evade the immune system. Cancer vaccines have become an attractive strategy to 
induce immune effector cell activation and subsequent tumour cell lysis, by utilizing tumour-
associated antigens and suitable adjuvants to induce an immune response. Cancer vaccines 
range from DC-based, DNA-based and recombinant protein-based to whole tumour cell 
vaccines.  
The PCa has been identified as an ideal malignancy for cancer vaccine targeting, due to the 
unique antigens that are expressed both by normal and cancerous cells, such as PSA and 
prostatic acid phosphatase (PAP).  
 Sipuleucel-T (Provenge™) was the first autologous DC-based vaccine approved by the 
FDA in 2010 for the treatment of metastatic CRPC and to date it is the only approved 
immunotherapeutic treatment for PCa (Sims 2012). It exploits the patient’s immune cells to 
target the cancer: peripheral blood mononuclear cells are isolated from the patient through 
leukapheresis and are then cocultured for 36 hours with a fusion protein combining PAP 
(indicative of cancer progression) and GM-CSF (added to stimulate APCs and obtain more 
mature DCs). They are then re-infused into the patient, and this product contains a very high 
number of DCs (5 x 107 cells), as well as a variable number of NK, T and B cells (Small, 
Schellhammer et al. 2006). This procedure is repeated three times every two weeks and it 
has shown to improve survival by 4.1 months, however it is a very expensive vaccine, costing 
around £80,000 per patient and only indicated for stage IV metastatic disease, when the 
patient’s immune system is already weakened. Hence, although Sipuleucel-T can activate 
cells such as natural killer (NK) cells and cytotoxic T cells to infiltrate the prostate, the tumour 
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microenvironment renders these cells anergic and/or suppressive, therefore tolerance in situ 
is not reversed.  
In a retrospective analysis of the data from the IMPACT (Immunotherapy for Prostate 
Adenocarcinoma Treatment) trial study, where Sipuleucel-T was compared to placebo in a 
phase III clinical trial, the patients with lower PSA levels at baseline had an increased survival 
benefit of 13 months compared to placebo, evidencing that immunosuppression leads to a 
higher tumour burden (Schellhammer, Chodak et al. 2013).  
Sipuleucel-T is currently tested in clinical trials in combination with other drugs like 
ipilimumab (NCT01832870), the radiotherapeutic drug Radium-223 (NCT02463799) and the 
hormone therapeutic drugs Abiraterone (NCT01487863) and Enzalutamide (NCT01981122).  
 GVAX (granulocyte-macrophage colony-stimulating factor tumour cell vaccine) is an 
example of a whole cancer-cell based vaccine that was tested for the treatment of hormone-
refractory PCA patients. It is derived from two allogeneic PCa cell lines, LNCaP (androgen 
dependent cell line, derived from lymph node metastasis) and PC-3 (androgen independent 
cell line, derived from bone metastasis), that are transfected with GM-CSF and irradiated for 
safety purposes. In phase I/II trials, chemotherapy-naïve with hormone-refractory PCa 
patients received GVAX and the results showed a safe toxicity profile as well as an increased 
overall survival of about 35 months in the high-dose group of patients. Based on these results 
two phase III trials started: VITAL-1 (Vaccine Immunotherapy with Allogeneic Prostate Cancer 
Cell Lines-1), which recruited asymptomatic patients to receive GVAX or docetaxel with 
prednisone and VITAL-2, which recruited symptomatic patients to receive combination of 
GVAX with docetaxel or docetaxel alone. VITAL-2 trial was terminated early due to a high 
mortality rate in the vaccine arm and VITAL-1 was also terminated due to an unplanned 
futility analysis that indicated that the trial had less than 30% chances of meeting its primary 
endpoint of an improvement in survival (Higano, Corman et al. 2008).  
Nevertheless, GVAX is currently tested in two different trials for the treatment of colorectal 
(NCT01952730) and of pancreatic cancer (NCT02004262), either alone or in combination 







The PCa microenvironment is very immunosuppressive and poorly immunogenic since 
all the infiltrating lymphocytes become anergic or suppressive once they enter the cancerous 
prostate. That is due to the presence of various suppressive cell populations or growth 
factors as mentioned earlier. Currently the only immunotherapeutic treatment that is 
approved by the FDA for PCa is Sipuleucel-T, with minimal results though, extending the 
lifespan by 4.1 months, and it is considered only at the metastatic stage of PCa, once the 
patient’s immune system is already greatly weakened.  
 
PCa is suitable for immunotherapy as it is a relatively slow growing cancer and immune 
responses take longer to mount a response compared to chemotherapy. It is critical though, 
to consider non-cell based immunotherapies for the treatment of PCa, as they have been 
previously used on patients with successful outcomes, as in the case of IL-2 that is FDA 
approved for use in melanoma and RCC. However, such cytokines are used systemically and 
hence can be extremely toxic, so they are only suitable for patients that are refractory to any 
other treatment. It has been further established that localized injection of IL-2 into a skin 
lesion can promote systemic activation of anti-tumour immunity to clear distant tumours 
(Johnson, Lum et al. 2008). Although when injected systemically, these proteins are very 
toxic, their localisation to the cancerous lesion would both increase their efficacy and lower 
their toxicity. Also when considering such agents for immunotherapies – it is vital to consider 
their actions at the site of the lesion where the immune system is most compromised. Many 
cytokines will have no effect when injected into this immunosuppressive environment.  
Lastly, it has been widely observed from several types of immunotherapies for various 
cancers that monotherapies are less efficacious compared to combinatorial treatments, so 








1.6 Aims and Hypotheses 
Preliminary data to this project from our laboratory (see Chapter 3), has shown that in 
an in vitro allogeneic coculture model of non-adherent peripheral blood mononuclear cells 
(PBMCs) with PCa cell lines (originating both from metastatic and non-metastatic cancer), 
that mimics the PCa microenvironment, IL-15, among a panel of Th1 therapeutic cytokines, 
was found to be the most potent activator of NK, NKT and CD8 T cells, aiding their cytotoxic 
activity towards the PCa cell lines (Elhage, Galustian et al. 2012). Based on this preliminary 
work and on the previous highlighted evidence, a number of hypotheses can be put forward, 
that were investigated in order to better understand how to harness immunotherapeutic 
agents such as IL-15 to treat PCa.  
 
These hypotheses are that: 
1. PCa can progress by tolerance to, and evasion of tumour cells from the immune-
system,  
2. Immunomodulatory targets in the PCa microenvironment expressed on either cells 
or in soluble form, are critical in this PCa progression.  
3. The tumour microenvironment represents the site of greatest immune tolerance and 
therefore, immune therapies targeting at the tumour microenvironment, rather than 
introduced systemically will break tolerance in situ and allow effective elimination of 
cancer cells. 
The aims of this project are: 
1. To create in vivo and in vitro models of prostate tumour-immune effector cell 
interaction and tumour cell killing, to enable us to identify, test and optimize novel 
immunotherapeutics 
2. To investigate the mechanisms of action of IL-15 on effector cell mediated killing of 
PCa cells in these models, focusing particularly on NK and NKT cells.  
The NK receptors and their ligands will be particularly studied, to investigate whether 
IL-15 modulates the expression and shedding of these ligands.  
3. To determine the efficacy of novel immunotherapeutics both singly and in 


































2.1 Materials and Reagents: 
2.1.1 Plasticware 
25cm2, 75cm2, 175cm2 tissue culture (TC) treated flasks (Greiner Bio-One Ltd, Stonehouse, 
UK) 
5ml, 10ml, 25ml serological pipettes (Greiner Bio-One Ltd) 
15ml, 50ml centrifuge tubes (Greiner Bio-One Ltd) 
6, 12, 24, 48, 96 – well plates, tissue culture treated (Greiner Bio-One Ltd) 
Filter system 0.22μm pore size, sterile (Corning, Flintshire, UK) 
1.5ml microcentrifuge tubes (ThermoFisher Scientific, Paisley, UK) 
1.5ml Cryovials (Corning) 
10ml Vacutainer™ tubes (Greiner-Bio One) 
40μm cell strainers (Greiner-Bio One) 
Polysine™ slides Menzel-Gläser (ThermoFisher Scientific) 
Cover slips 24*64mm No 0 (SLS, Nottingham, UK) 
G-25 mini columns (GE Healthcare, Buckinghamshire, UK) 
3K desalting columns (Amicon, Watford, UK) 
Float-A-Lyzer dialysis units (Spectrum labs, California, USA) 
 
2.1.2 Molecular Biology Reagents 
Dimethyl sulfoxide (DMSO) (Sigma-Aldrich, Gillingham, UK) 
Ethanol (Sigma-Aldrich) 
Acetone (Sigma-Aldrich) 
Phytohemmaglutinin (PHA) (ThermoFisher Scientific) 
 
2.1.3 Tissue culture reagents  
RPMI-1640 Medium with Sodium Bicarbonate (Sigma-Aldrich) 
RPMI-1640 Medium, no phenol red (Life Technologies, Paisley, UK) 
Dulbecco’s Modified Eagle’s Medium (DMEM)- high glucose (Sigma-Aldrich) 
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Hanks’ balanced salt solution (HBSS) (Sigma-Aldrich) 
Gentamicin solution sterile filtered (Sigma-Aldrich) 
Accutase (Sigma-Aldrich) 
Phosphate buffered saline (Severn Biotech Ltd, Worcestershire, UK) 
L-glutamine solution (Sigma-Aldrich) 
Antibiotic-antimycotic solution (Sigma-Aldrich) 
MycoZap prophylactic (Lonza, Berkshire, UK) 
Trypan blue (Sigma-Aldrich) 
Foetal Bovine Serum Certified (Life technologies) 
Bovine insulin (Sigma-Aldrich) 
Dehydroisoandrosterone (Sigma-Aldrich) 
CellTitre 96® Aqueous One Solution Cell Proliferation Reagent (Promega, Southampton, UK) 
Histopaque-1077 Hybri-max (Sigma-Aldrich) 
10x RBC lysis buffer (eBioscience, Altrincham, UK) 
Diamedix™ 24EZ Complement Cells (Fisher Scientific, Paisley, UK) 
 
2.1.4 Antibodies and cytokines 
Human Interleukin-2 (Peprotech, London, UK) 
Human Interleukin -12 (Peprotech) 
Human Interleukin -15 (Peprotech) 
Human Interleukin -21 (Peprotech) 
Human IFNγ (Peprotech) 
Murine Interleukin-2 (Peprotech) 
Murine Interleukin -12 (Peprotech) 
Murine Interleukin -15 (Peprotech) 
Murine Interleukin -21 (Peprotech) 
Murine IFNγ (Peprotech) 
Recombinant human Interleukin-15 (Genscript, Hong Kong, China) 




Ultra-LEAF™ Purified Mouse IgG1, κ Isotype Ctrl Antibody [Clone: MOPC-21] (Biolegend UK 
Ltd) 
Human MICA MAb (Clone 159227) (Bio-techne, Abingdon, UK) 
Mouse IgG2B Isotype Control (Clone 20116) (Bio-techne) 
Annexin V apoptosis detection kit APC (eBioscience) 
Fc block, human or mouse (Miltenyi Biotec, Surrey, UK) 
Anti-PTL033, Clone UC10-4F10-11 (BioXcell, New Hampshire, USA) 
Anti-PTL035, Clone 10F.9G2 (BioXcell) 
Recombinant mouse PTL033/Fc Chimera (SinoBiologicals Inc., Beijing, China) 
Recombinant mouse PTL035/Fc Chimera (SinoBiologicals Inc.) 























Species Antigen Fluorophore Clone Manufacturer 
Human CD3 FITC HIT3a SantaCruz Biotechnology, Heidelberg, 
Germany 
Human CD3 PE HIT3a Biolegend 
Human CD3 APC HIT3a Biolegend 
Human CD8 PerCP BW135/80 Miltenyi Biotec 
Human CD56 PE MEM-188 Biolegend 
Human CD56 APC MEM-188 Biolegend 
Human FoxP3 PE 206D Biolegend 
Human CD107a APC H4A3 Biolegend 
Human Perforin FITC dG9 Biolegend 
Human CD158a/h FITC HP-MA4 Biolegend 
Human CD158b FITC DX27 Biolegend 
Human CD158e1 FITC DX9 Biolegend 
Human CD226 FITC 11A8 Biolegend 
Human CD314 FITC 1D11 Biolegend 
Human CD335 FITC 9E2 Biolegend 
Human CD336 Alexa Fluor 488 3.43 Biolegend 
Human NKp30 FITC P30-15 Biolegend 
Human MICA/B FITC 6D4 BioRad AbD Serotec, Paisley, UK 
Human MICA FITC 4 Biorbyt, Cambridge, UK 
Human MICA PE 159227 Biolegend 
Human ULBP1 FITC polyclonal Biorbyt 
Human Nectin-2 FITC polyclonal Biorbyt 
Human HLA-A,B,C FITC W6/32 Biolegend 
Human HLA Class I FITC Tu149 Life Technologies 
Human HLA-I Bw4 FITC 0.L.6 US Biologicals, California, USA 
Human HLA-G FITC 4H84 SantaCruz Biotechnology 
Human IL-15 PE  IC2471D Bio-Techne 
Human PTL035 PE 29E.2A3 eBioscience 
Human PTL033 APC L3D10 Biolegend 
Murine NK 1.1 Alexa Fluor 647 PK136 Biolegend 
Murine CD3 FITC 17A2 Biolegend 
Murine CD4 FITC GK1.5 eBioscience 
Murine CD8 PerCP/Cy5.5 53-6.7 Biolegend 
Murine CD25 FITC 3C7 Biolegend 
Murine FoxP3 PE MF-14 Biolegend 
Table 2.1: Antibodies used for FCAS staining 
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2.1.5 Biochemistry reagents 
Phosphate buffered saline x1 sterile (Severn Biotech) 
Bovine Serum Albumin (Sigma- Aldrich) 
Cell fix 10x (BD Biosciences, Oxford, UK) 
TCEP (ThermoFisher Scientific) 
12% and 4-12% Bis-Tris NuPage™ gels (Life Technologies)  
NuPage™ LDS loading buffer (Life Technologies) 
Mark12™ Unstained Standard (ThermoFisher Scientific) 
Novex® Sharp Unstained Protein Standard (ThermoFisher Scientific) 
SafeStain (GE Healthcare) 
SimplyBlue™ SafeStain (ThermoFisher Scientific) 
iBlot® Dry Blotting System (Life Technologies) 
Caseine (Sigma-Aldrich) 
SIGMAFAST™ 3,3’diaminobenzadine tablets (Sigma Aldrich) 
AnaTag™ (AnaSpec, Inc, California, USA) 
Hydrogen peroxide solution 30% (w/w) in H2O (Sigma-Aldrich) 
 
2.1.6 Cytotopic modification agent 
PTL3146: The tail used for modification of the IL-15 and the two antibodies to immune 
checkpoint inhibitors was kindly provided by Dr Richard Smith, Director of the Protein 
Therapeutics Laboratory at the MRC Centre for Transplantation, King’s College London. The 
tail sequence is (α,ε bis-myristoyl lysine) SSKSPSKKDDKKPGD(S-2-pyridyldithio)-C-acid.  
 
2.1.7 Commercial kits: ELISA, Isolation Kits, Intracellular staining kit, Biochemical 
assays 
Pan T cell Isolation Kit II, mouse (Miltenyi Biotec) 
NK Cell Isolation Kit II, mouse (Miltenyi Biotec) 
MICA ELISA kit, human (Promocell, Heidelberg, Germany) 
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Human CD112/ Nectin-2/ PVRL2 ELISA (SinoBiologicals, Inc) 
Human IL-2 ELISA MAX™ Deluxe (Biolegend) 
Cytofix/Cytoperm Soln Kit (BD Biosciences) 
SilverXpress® Silver staining kit (Life Technologies) 
Pierce™ Coomassie (Bradford) Protein Assay Kit (ThermoFisher Scientific) 
 
2.1.8 Buffers 
Buffers that were used regularly in this thesis and that are not components of commercial 
kits, are listed below: 
FACS buffer 
1% PBS (OXOID, Hampshire, UK) 
0.1% Sodium Azide (Severn Biotech) 
1% Bovine Serum Albumin (Sigma Aldrich) 
Isolation Buffer 
0.5% Bovine Serum Albumin (Sigma Aldrich) 
2mM EDTA (Sigma Aldrich) 
PBS (Severn Biotech) 
pH 7.2, sterile filtered  
 
2.1.9 Cell culture media and Serum 
Foetal Bovine Serum (FBS): FBS was heat inactivated by incubation in a water bath at 57°C for 
1 hour and stored in aliquots at -20°C thereafter.  
RPMI complete medium: RPMI-1640 supplemented with 10% FBS, 10ml/L 
antibiotic/antimycotic solution, 2mM L-glutamine, 20μg/ml gentamicin, 1x mycozap 
prophylactic. Sterile-filtered. RPMI phenol-free complete medium was prepared with the 
same supplements.  
DMEM complete medium: DMEM- high glucose medium supplemented with 10% FBS, 10ml/L 
antibiotic/antimycotic solution, 2mM L-glutamine, 20μg/ml gentamicin, 1x mycozap 
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prophylactic, 5% Nu Serum IV, 10nM dehydroisoandrosterone, 0.005mg/ml bovine insulin. 
Sterile filtered.  
 
2.1.10 Cell lines 
PC-3 (ATCC® CRL-1435™): An epithelial cell line derived from a 62- year- old Caucasian male 
with a grade IV prostate adenocarcinoma, metastasised to the bone. It’s highly tumorigenic 
androgen- independent cell line that was first established in 1979 (Kaighn, Narayan et al. 
1979). The PC-3 cell line was obtained from ATCC.  
LNCaP (ATCC® CRL-1740™): An epithelial cell line derived from the left supraclavicular lymph 
node of a 50- year- old Caucasian male with a metastatic prostate carcinoma. It is an 
androgen dependent cell line that was first established in 1980 (Horoszewicz, Leong et al. 
1980). The cell line was obtained from ATCC.  
CTLL-2 ATCC® TIM-214™): A cell line that is a clone of cytotoxic T cells derived from a C57BL/6 
mouse. They were first established in 1977 (Gillis and Smith 1977).  
TRAMP-C1 (ATCC® CRL-2740™) and – C2 (ATCC® CRL-2731™) : Transgenic Adenocarcinoma of 
the Mouse Prostate cell lines 1 and 2 were derived from a 32-week-old C57Bl/6 mouse with a 
primary prostate tumour. They are of epithelial origin and were first established in 1996 
(Greenberg 1996).  Both cell lines are highly tumourigenic when injected in C57BL/6 mice, 
although TRAMP-C1 is reported to grow faster that TRAMP-C2 in vitro and in vivo (Foster, 
Gingrich et al. 1997). Both cell lines were obtained from ATCC.   
EL4 (ATCC® TIM-39™): A cell line resembling T lymphocytes that was isolated from a 
lymphoma in a C57BL/6 mouse (Gorer 1950, Old, Boyse et al. 1965). This cell line was a kind 
donation by Dr. Giorgia Fanelli from the Immunoregulation Laboratory at the MRC Centre for 
Transplantation, King’s College London.  
Jurkat (ATCC® TIB-152™): A T-lymphocyte-like cell line that was isolated from the peripheral 
blood cells of a 14-year old boy with T cell leukaemia (Gillis and Smith 1977). The cell line was 






2.1.11 In vivo experiments 
Animals and apparatus 
Inbred male C57BL/6 Jax strain mice (catalog number 000664), aged 6-8 weeks, were 
obtained from The Jackson Laboratory. 
Digital Vernier Caliper (Harvard apparatus) 
 
Buffers 
Fc block:  
10% FBS (Life technologies) 
1% Bovine Serum Albumin (Sigma Aldrich) 
1x Blocking buffer (Abcam) 
 
Immunohistochemistry/H&E reagents and antibodies 
Streptavidin/Biotin Blocking kit (Vector Laboratories Inc.) 
Vectashield mounting medium for fluorescence with DAPI (Vector Laboratories Inc.) 
Vectashield mounting medium for fluorescence Hard Set (Vector Laboratories Inc.) 
Haematoxylin (RA Lamb- ThermoFisher Scientific) 
Eosin (RA Lamb- ThermoFisher Scientific) 
Xylene (Sigma Aldrich) 
Optimal cutting temperature compound (OCT) (Fisher Scientific) 
DPX (Diputyl Phthalate containing Xylene) (VWR) 
CD3 Armenian hamster monoclonal antibody (Abcam) 
CD4 goat polyclonal antibody (SantaCruz Biotechnology) 
CD8-a rabbit polyclonal antibody (SantaCruz Antibody) 
IL2Rα rabbit polyclonal antibody (SantaCruz Biotechnology) 
FoxP3 anti-mouse/rat biotin (eBioscience) 
NK1.1/CD161 rabbit polyclonal antibody (Bioss Antibodies) 
AMCA donkey anti-goat IgG (Stratech Scientific Ltd) 
Rhodamine (TRITC) donkey anti-rabbit IgG (Stratech Scientific Ltd) 
Alexa Fluor 568 goat anti-hamster IgG (ThermoFisher Scientifc) 
FITC donkey anti-rabbit IgG (Stratech Scientific Ltd) 
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Alexa Fluor 488 donkey anti-rat IgG (Stratech Scientific Ltd) 
Streptavidin FITC (BD Biosciences) 
 
2.2 Methods: 
2.2.1 Cell culture  
2.2.1.1 Culture of adherent and suspension cell lines 
All adherent cell lines were grown in 175cm2 TC flasks, at 37°C in a 5% CO2 humidified 
incubator, until 70-80% confluency was reached (every 4-5 days). PC-3 and LNCaP cells were 
grown in RPMI complete medium, whereas TrampC cells in DMEM complete medium. Their 
passage included removal of the culture medium and addition of 7ml accutase (detachment 
reagent) for 10-15min. Cells were then washed in HBSS, resuspended in 5ml of culture 
medium, counted and seeded at 1.5*106/ml cell density in 30ml of complete medium.  
The CTLL-2 cell line was grown in suspension in 75cm2 TC flasks, at 37°C in a 5% CO2 
humidified incubator. The cells were maintained at a concentration of 6-9*105 cells/ml by the 
addition of fresh RPMI complete culture medium once per week and the addition of 10-
20IU/ml IL-2 twice per week.  
The EL-4 and Jurkat cell lines were grown in suspension in 75cm2 TC flasks, at 37°C in a 5% 
CO2 humidified incubator. The cells were maintained at a concentration of 4-6x10
5 cells/ml 
by the addition of fresh RPMI complete culture medium three times per week. 
 
2.2.1.2 Cryopreservation and thawing of cells 
For long term storage cells were stored in liquid nitrogen or in the -80°C freezer. For freezing 
the cells were resuspended in 90% FBS + 10% DMSO freezing medium at concentrations of 2-
4x106 cells/ml and stored in cryovials.  
The vials were thawed in a water bath at 37°C and transferred in RPMI complete medium, 
centrifuged at 400g for 5 min to remove the excess freezing medium; they were then 




2.2.1.3 Peripheral Blood Mononuclear Cell (PBMC) Isolation  
PBMCs from healthy donors were isolated by Ficoll- Histopaque density gradient 
centrifugation, following the protocol described by Malkovsky and Sondel (1987) (Malkovsky 
and Sondel 1987). Briefly, blood samples from healthy donors were diluted 1:1 with HBSS and 
layered on top of Histopaque, at a 1:2 Histopaque to blood ratio. The samples were then 
centrifuged at 1600 RPM, with no deceleration, at room temperature for 30 min. PBMCs 
were then extracted from the buffy coat, washed with HBSS, resuspended in 10ml of red 
blood cell lysis buffer and incubated at 37°C in a 5% CO2 humidified incubator for 10 min. 
Washing with HBSS proceeded and the cells were then resuspended in RPMI complete 
medium and counted. Cells were resuspended at a concentration of 3x106 cells/ml in a 
175cm2 TC flask and incubated for a minimum of 3 hours or overnight. This step is called 
plastic- adherence step; the non-adherent PBMCs contain the fraction of cells (e.g. T, B cells) 
that was used for further experiments.  
 
2.2.1.4 Murine splenocyte isolation and subsequent NK and T cell purification 
Inbred male C57BL/6 JAX strain mice, aged 6-8 weeks, were obtained from the Jackson 
laboratory. The spleen was extracted from a mouse, kept in sterile filtered PBS and was 
processed within minutes of removal from the mouse, to minimise the apoptotic splenocyte 
number.  
The spleen was placed on a 40μm cell strainer placed over a 50ml centrifuge tube and 
pushed through the strainer with the plunger of a syringe, while keeping both the spleen and 
the membrane of the strainer wet with PBS. The cells that passed through the strainer were 
washed with HBSS, resuspended in 5ml of red blood cell lysis buffer and incubated at 37°C in 
a 5% CO2 humidified incubator for 5 min. They were then washed with HBSS and 
resuspended in RPMI complete medium. The cells were counted and subsequent NK or T cell 
purification proceeded.  
Murine splenic T lymphocytes were isolated using a Pan T cell isolation kit (Felio, Nguyen et 
al. 2009). The NK cells from the splenic lymphocytes were enriched using an NK cell isolation 
kit (40% purity) (Meinhardt, Kroeger et al. 2012). The manufacturer’s protocol was followed 
for all cell purifications.  
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2.2.2 Creation of in vitro allogeneic and syngeneic coculture models of immune 
effector cell – target cell interaction 
2.2.2.1 Allogeneic coculture model 
The non-adherent fraction of PBMCs was cocultured in RPMI phenol-free complete medium, 
in the presence or absence of human PCa cell lines (PC-3 or LNCaP), at an effector to target 
(E:T) ratio that ranged from 0.5:1-20:1, in the presence or absence (control) of human 
recombinant cytokines in a 24-well plate for 7 days. The cytokines tested were: IL-2 (1 or 
10ng/ml), IFNγ (2.5ng/ml), IL-12 (2.5ng/ml), IL-15 (2.5ng/ml) and IL-21 (2.5ng/ml). The 
concentration of target cells was 2x105 cells/ml and that of the immune effector cells was 
8x105 cells/ml.  
This allogeneic coculture model was also used for NKG2D and MICA blocking, where 10μg/ml 
of aNKG2D blocking antibody or 5 μg/ml of aMICA were added to the cocultured cells. Their 
corresponding isotypes (IgG1 or IgG2b) were used as controls and added on separate wells of 
cocultured cells at the same concentrations.   
 
2.2.2.2 Syngeneic coculture model 
NK enriched or T enriched cells from splenocytes of a C57BL/6 mouse, were cocultured in 
RPMI phenol-free complete medium in the presence or absence of a murine PCa cell lines, 
called TRAMP-C1, at an E:T ratio of 4:1 – also optimised as in the allogeneic model (results 
shown in chapter 3)-, in the presence or absence (served as control) of murine recombinant 
cytokines in a 24-well plate for 9 days. The cytokines tested were: murine IL-2 (1 or 10ng/ml), 
IFNγ (2.5ng/ml), IL-12 (2.5ng/ml), IL-15 (2.5ng/ml) and IL-21 (2.5ng/ml). The concentration of 








2.2.3 Cellular assays 
2.2.3.1 Cell surface staining 
Cells were transferred to FACS tubes and washed twice with 1ml FACS buffer and 
centrifuged. Samples were then Fc blocked for 15 min, and incubated with antibodies at 4°C 
in the dark for 45 min. Samples were then washed, centrifuged and resuspended in 300μl cell 
fix. Cells were acquired with a FACS Calibur flow cytometer (BD Biosciences) and analysed 
using FlowJo software. 
  
2.2.3.2 Intracellular staining 
Intracellular staining was performed for the human and murine FoxP3 and perforin 
antibodies using the Cytofix/Cytoperm, Fixation and Permeabilization kit from BD 
Biosciences. The protocol was followed as per manufacturer’s instructions; briefly, following 
cell surface staining, the cells were permeabilized using the fix/perm solution at room 
temperature for 20 min, washed with the perm/wash buffer and centrifuged. The antibodies 
were added to the samples which were then incubated in the dark at room temperature for 
30 min. The cells were then washed with the same perm/wash buffer, centrifuged and 
resuspended in 300μl cell fix. They were acquired using a FACS Calibur flow cytometer (BD 
Biosciences) (Cell quest software) and analysed using FlowJo software.  
 
2.2.3.3 Annexin V/PI staining for the detection of apoptotic/necrotic PCa cells 
Induction of apoptosis and necrosis were investigated using the Annexin V apoptosis 
detection kit by eBioscience, which contained annexin V conjugated to APC and propidium 
iodide (PI) conjugated to PE/PerCP.  
Briefly, the cells from each well of the 24-well plate were added to FACS tubes and the wells 
were washed with 500μl PBS. 200μl of accutase were added to each well, so that all the PCa 
cells that were attached at the bottom of the plate, detach. The cells were then washed once 
with PBS, centrifuged for 5 min, washed with 1x annexin binding buffer (1x ABB), centrifuged 
for 5 min and resuspended in 100μl 1x ABB. 5μl of Annexin V APC were added to each 
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sample, which were then incubated for 15min in the dark. The cells were washed again with 
1x ABB, centrifuged for 5 min and resuspended in 200μl 1x ABB. 5μl of PI were added to each 
sample and they were acquired using a FACS Calibur machine.  
In order to observe the maximum cell death that PCa cells could achieve and hence have a 
positive control for the experiment, 600μM of H2O2 were added to PCa cells in the 24 well 
plate and incubated for 24 hours. The next day the PCa cells with H2O2 were tested for 
























2.2.3.4 Gating strategy and analysis for NK and NKT cells 
A representative surface staining gating strategy is shown in figure 6. Non-adherent PBMCs 
were cocultured with LNCaP cells under different conditions for 7 days and the cells were 
stained for CD56 and CD3. The gating of viable cells using forward and side scatter is shown 
on the top panels, where both the location of LNCaP cells is seen as well as the location of 
the lymphocytes. The bottom panels show the NK and NKT cells from the lymphocytes’ gate, 
as observed by CD56+ CD3- and CD56+ CD3+ staining respectively.  
Similar approach was adopted on the analysis of other phenotypic markers.  
 
 
Figure 2.1: Gating strategy for lymphocytes, NK and NKT cells. A representative cell surface staining 
experiment is shown, following coculture of non-adherent PBMCs with LNCaP cells, either without 
cytokines, or with IL-2 or IL-15 for 7 days. The viable lymphocytes and LNCaP cells on the top panels 
are gated accordingly. The bottom panels have as a parental population the lymphocytes, from which 








2.2.3.5 Viability/proliferation assay to confirm the activity of IL-15  
Cell proliferation and viability were measured using the Celltitre96® Aqueous One solution 
cell proliferation assay (MTS) by Promega. This is a colourimetric assay utilizing a tetrazolium 
compound [3-(4,5-dimethylthiazol-2-yl)-5-(3- carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt; MTS] and an electron coupling reagent (phenazine ethosulfate; PES) 
which when cultured with metabolically active cells result in the generation of a formazan 
product, which absorbs light at a wavelength of 490nm. The resulting absorbance is directly 
proportional to the number of viable cells in culture.  
The CTLL-2 cells were added to a 96-well plate at a concentration of 5 x 105 cells/ml. The cells 
were incubated for 72 hours in the presence or absence of cytokines and 20μl of the MTS 
reagent were added to each well (100μl cell suspension). The plate was incubated in the dark 
at 37°C in a humidified, 5% CO2 environment for 4 hours. 25μl of 10% SDS were added to 
each well to stop the reaction. The plate was read at 450nm using a 96-well plate reader 
(Molecular Devices, UK). 
 
2.2.3.6 Jurkat cell- based assay for the detection of tailed PTL033 activity 
(performed by Dr. Dorota Smolarek) 
Jurkat cells at a concentration of 105 cells per 100μl were added on a 96-well plate and 
activated using 2.5μg/ml of PHA and 2μg/ml of soluble Fc chimera protein that is responsible 
for the cell activation In order to inhibit the cell activation, 2μg/ml of soluble Fc chimera 
protein to the immune checkpoint inhibitor were added, followed by varying concentrations 
of the antibody to immune checkpoint inhibitor, tailed or untailed. Cells were then incubated 
for 4 hours at 37°C in a humidified, 5% CO2 environment. The plate was centrifuged at 400g 
for 5mins and the supernatants were collected and analysed for the soluble secretion of IL-2 






2.2.3.7 EL4 cell- based assay for the verification of tailed PTL035 activity 
(performed by Dr. Dorota Smolarek) 
EL4 cells at a concentration of 105 cells per 100μl were incubated with a PE-labelled anti-
mouse to the immune checkpoint inhibitor antibody in order to establish binding with the 
immune checkpoint inhibitor’s receptor on their surface, followed by the addition of 50μg/ml 
Fc to immune checkpoint inhibitor protein, in order to disturb the immune checkpoint 
inhibitor’s receptor binding, followed by the addition of varying concentrations of antibody to 
the immune checkpoint inhibitor, in order to reconstitute binding of fluorescently labelled 
antibody to the immune checkpoint inhibitor. The samples were incubated at 4°C in the dark 
for 45 min. Samples were then washed, centrifuged and resuspended in 300μl PBS. Cells 
were acquired with a FACS Calibur flow cytometer (BD Biosciences). 
 
2.2.4 Biochemical assays 
2.2.4.1 MICA and Nectin-2 Enzyme - Linked Immunosorbent Assays (ELISA) 
Supernatants from the allogeneic coculture model were collected and were analysed for the 
soluble expression of MICA (Allez, Tieng et al. 2007) and of Nectin-2 (Bachelet, Munitz et al. 
2006) by ELISAs (Promocell and SINO Biologicals) , as per manufacturer instructions.  
 
2.2.4.2 Tailing of IL-15 (performed by Dr. Dorota Smolarek) 
0.5mg/ml of human recombinant IL-15 was incubated (rotating) with TCEP at a final 
concentration of 300μM, for 45-60min. The mixture was then applied on a G-25 mini column, 
so that excess TCEP was removed. The tail was added to IL-15 at a 1:3 IL-15 to tail molar ratio 
and incubated for 60-90 min at room temperature, followed by overnight incubation 
(rotating) at 4°C. The mixture was then dialysed against 1L of PBS for a day using a dialysis 
unit (Float-A-Lyzer, Spectra/Por) according to manufacturer’s instructions; the PBS was then 
discarded and fresh PBS was added for an overnight dialysis. The next day the mixture of IL-
15 with the tail was analysed on an SDS-PAGE and the concentration was assayed by 
Coomasie Protein Assay (ThermoFisher Scientific) (Bradford 1976). 
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2.2.4.3 Tailing of the antibodies to immune checkpoint inhibitors (performed by 
Dr. Dorota Smolarek) 
The two antibodies of interest were modified with 2-iminothiolane (2-IT), a reagent that is 
used to incorporate thiol groups into protein by interaction with lysine amino groups (Smith 
and Cassels 1988).  
First the antibodies (1mg/ml), water and PBS were degassed under the vacuum for one hour. 
2-IT was dissolved in water at a 100mM concentration. 5μl of 2-IT (final concentration 2mM) 
was added to the antibody solution and incubated at room temperature for 30min. 8μl of 
10mM tail solution (approximately 1:3 antibody to tail molar ratio) were added to the 
mixture of antibody and 2-IT with vortexing. The reaction mixture was incubated at room 
temperature for 5min, while monitoring the reaction by measuring its absorbance at A343 
with a spectrophotometer. The reaction mixture was then applied on a G-25 mini-column at 
room temperature and separation of antibody from excess of 2-IT and tail was done using a 
spin protocol method. The antibody-tail mixture was analysed by SDS-PAGE.  
 
2.2.4.4 SDS-PAGE (performed by Dr. Dorota Smolarek) 
The sodium dodecyl-sulphate - polyacrylamide- gel electrophoresis (SDS-PAGE) technique 
was employed for the electrophoretic separation of proteins. 4-12% Bis-Tris NuPage™ pre-
casted gels were used for the detection of the antibodies, and 12% Bis-Tris NuPage™ gels for 
the detection of IL-15. Gels were loaded into the XCell SureLock® Mini-Cell gel tank (Novex, 
Life Technologies) and the tank was filled with MES-SDS or MOPS running buffer, for IL-15 
and for the antibodies respectively. The samples to be tested were added NuPage™ LDS 
loading buffer and loaded on the gel. A standard molecular size marker (Novex® Sharp 
unstained protein standard or Mark12™ unstained standard) was used. The gel was run at 







2.2.4.5 SDS-PAGE gel staining (performed by Dr. Dorota Smolarek) 
Silver staining for total IL-15 (tailed and untailed) protein was performed using the 
SilverXpress® Silver Staining kit following a protocol as per manufacturer instructions. The 
antibodies underwent staining with the SimplyBlue™ SafeStain as per manufacturer 
instructions.  
 
2.2.4.6 Western Blotting (performed by Dr. Dorota Smolarek) 
Proteins separated on the SDS-PAGE gel were transferred to nitrocellulose membranes by 
dry-transfer using the Life Technologies’ iBlot® system, then the membrane was blocked 
using Casein for 1 hour. The membrane was then washed 3 times with water, the primary 
antibody was applied (diluted in PBS) and incubated at room temperature for 1 hour. The 
membrane was washed again 3 times in water and the secondary antibody was applied 
(diluted in PBS).  The membrane was washed again and the blot was developed using 
SIGMAFAST™ 3,3’diaminobenzadine tablets as per manufacturer’s protocol.  
 
2.2.4.7 Fluorescein amidite (FAM) labelling of the tail (performed by Dr. Dorota 
Smolarek) 
The tail was FAM labelled using the AnaTag™ kit in order to confirm protein tailing. The 
protocol followed was as per manufacturer’s instructions; briefly 230μg of the tail was mixed 
with FAM dye, reconstituted in DMSO, at a 1:2 tail to dye molar ratio and the mixture was 
incubated rotating for 3 hours. Then the unconjugated dye was removed by dialysis against 
PBS, changing the buffer twice, finally the mixture of tail with FAM dye was concentrated to 
100μl using 3K cut off Amicon Ultra-0.5 Centrifugal Filter Unit (Merc Millipore). The tail was 
then ready to be used in protein modification. The SDS-PAGE gels were run as described 
above, and the bands were visualised under UV light using a G:BOX gel imagine device 





2.2.5 In vivo experiments  
All experiments were performed in accordance with the UK Home Office Animals Scientific 
Procedures Act 1986 under Project Licence Number (PPL): 70/7743 and Personal Licence 
Number (PIL):  70/24581 
 
2.2.5.1 Subcutaneous implantation of PCa cells on C57BL/6 mice 
Inbred male 6-8 weeks old C57BL/6 JAX strain mice (from The Jackson Laboratory, UK) were 
subcutaneously injected with 5x106 TRAMP-C2 cells in 100μl PBS into the left flank under 
isoflurane anaesthesia in 1% N2O, 2% O2. Tumour dimensions were monitored daily or every 
other day, when the tumour was palpable it was measured using calipers and the tumour 
volume was calculated using the formula where only one dimension is known  
 
 
    . 
 
2.2.5.2 Subcutaneous injection of the cocktail of drugs (IL-15 and two antibodies) 
On the day that the tumours on mice were palpable (between 30-40mm3), the mice were 
divided in three groups (10 mice in each group) and injected with the sterile-filtered cocktail 
of drugs. Each mouse was injected subcutaneously in the close vicinity of the tumour with 
either 100μl of sterile-filtered PBS (group 1), or with 100μl of a cocktail of untailed drugs: 5μg 
IL-15 and 100μg of each antibody, prepared in PBS (group 2) or with the tailed version of the 
cocktail of drugs (group 3) at the same concentrations in PBS (5μg IL-15, and 100μg of each 
antibody). The mice were injected only once and by day 73 they were all culled.  
 
2.2.6 Histological procedures 
At the time that the mice were culled their tumour masses were extracted and preserved in 
Optimal Cutting Temperature (OCT) cryo-embedding medium and at liquid nitrogen until 
further use. Tissue sections of 2μm were cut using a sledge microtome (Leica, UK) and 
transferred onto Polysine™ slides and allowed to air-dry overnight. They were stored at -
80°C, if not used immediately.  
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2.2.6.1 Haematoxylin & Eosin (H&E) staining 
H&E staining was performed on the tumour tissue sections from the different groups of mice; 
Haemotoxylin stains the nuclei of cells dark blue and the cytoplasm pink by eosin.  
Slides with the tissue sections were immersed in haematoxylin for 7 minutes, followed by a 
15-20min wash with running water. Sections were then dipped in eosin for 5 minutes and 
rinsed briefly in water. They were then dehydrated by immersing through an increasing 
concentration of alcohol (90%, 100%). Finally, sections were cleared in xylene and mounted 
in DPX (dibutyl phthalate containing xylene).  
 
2.2.6.2 Immunofluorescence staining 
The slides with the tissue sections were removed from the -80°C and air dried for 20min. Cold 
acetone was poured on the slides which were stored at -20°C for 10min. They were air dried 
again for 20min. Wax pen was applied around the tissue section, which was then blocked 
with 1x casein blocking buffer for 1 hour. If the antibody of interest was biotinylated, 
streptavidin was applied for 15min, washed twice with PBS, biotin was applied for 15min and 
the slides were washed twice again with PBS. Fc block was then added and incubated for one 
hour. The primary antibody was applied on the slides which were incubated for 1 hour, 
followed by washing three times with PBS and application of the secondary antibody, and 
incubation for another 1 hour. Both antibodies were diluted in blocking buffer and 1% BSA. 
The slides were washed three times with PBS and Vectashield mounting medium was applied. 










2.2.7 Statistical analysis 
Statistical analysis was performed using GraphPad Prism 6 (GraphPad Software Inc., USA). 
The appropriate significance testing (i.e. one-way ANOVA) with a 5% confidence level was 
used according to the type of data and results were presented as the mean ± standard error 



















Design of an allogeneic prostate tumour cell – immune effector cell 
















3.1 Introduction  
The PCa microenvironment is a highly immunosuppressive and poorly immunogenic 
environment, where the infiltrating immune cells become anergic or suppressive. The aim of 
this project was to overcome this immunosuppression by enhancing the immune effector 
cells. In order to mimic this microenvironment it was critical to design in vitro and in vivo 
models of the prostate tumour –immune effector cell interaction and tumour cell killing that 
would mimic the prostate tumour microenvironment and would enable us to identify, test 
and optimize novel immunotherapeutics. Two models were designed in this project, an 
allogeneic and a syngeneic (in order to investigate any alloreactivity effects), where immune 
effector cells were cocultured with PCa cell lines, in the presence of a panel of Th1 cytokines; 
the expansion and activity (target cell killing) of the immune effector cells in both the 
allogeneic and syngeneic coculture models were investigated. 
 
Regarding the allogeneic coculture model, the non-adherent fraction of PBMCs from 
healthy blood donors, was cocultured with PC-3 and LNCaP cell lines, whereas in the 
syngeneic coculture model, NK- or T- purified cells isolated from splenocytes of C57BL/6 
mice, were cocultured with the TRAMP-C1 cell line, which is also an isolated cell line from the 
prostate of a C57BL/6 mouse with transgenic adenocarcinoma. In both coculture models, a 
panel of therapeutic cytokines were studied and included IL-2, IL-12, IL-15, IL-21 and IFNγ, 
due to their clinical and therapeutic implication.  
 
Preliminary data to this project have shown that in an allogeneic coculture system of 
immune effector cells with PCa cell lines (PC-3 and LNCaP) IL-15 is the most potent activator 
of NK cell and of CD8 T cell expansion, as observed by CD56+ CD3- cell expression (Figure 3.1) 
and CD8+ CD4- cell expression (Figure 3.2) respectively (n=5, *p<0.01, one-way ANOVA). The 
effects of IL-15 were compared to control (no cytokine) or other therapeutic Th1 cytokines 
including ΙL-2, IFNγ, IL-12 and IL-21.  IL-15 also increased the perforin expression by NK and 
CD8 T cells as well as the killing of PCa cells, as detected by Annexin+ PI+ PCa cell expression 
(n=5, *p<0.001, one-way ANOVA) (Figure 3.3).  IL-15 did not affect the T-regulatory cell 
expansion, as observed by CD4+ CD25+ FoxP3+ T cell expression, when compared to control or 
the other cytokines, whereas IL-2 highly expanded them (n=5, *p<0.05, **p<0.01, 1-way 
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ANOVA) (Figure 3.4). The ratio of immune effector cells to target cells (E:T) at the allogeneic 
coculture model that has been used to generate these preliminary data, was 8:1 (1.6x106/ml 




Figure 3.1: CD3 and CD56 cell staining in cocultures of non-adherent PBMCs and PC-3 or LNCaP cells. 
The NK cell expansion, as observed by CD56+ CD3- cell staining, within the non-adherent fraction of 
PBMCs is shown, in the absence or presence of LNCaP or PC-3 cells, in the presence or absence of a 
panel of therapeutic Th1 cytokines (10ng/ml IL-2, 25ng/ml IFNγ, 25ng/ml IL-12, 25ng/ml IL-15, 
25ng/ml IL-21). The dotplots are showing the NK cell expansion in the absence or presence of 










Figure 3.2: CD4 and CD8 cell staining in cocultures of non-adherent PBMCs and PC-3 or LNCaP cells. 
The CD8 T cell expansion, as observed by CD8 and CD4 markers’ staining, within the non-adherent 
fraction of PBMCs is shown, in the absence or presence of LNCaP or PC-3 cells, in the presence or 
absence of a panel of therapeutic Th1 cytokines (10ng/ml IL-2, 25ng/ml IFNγ, 25ng/ml IL-12, 25ng/ml 
IL-15, 25ng/ml IL-21). The dotplots are showing the CD8+ cell expansion in the absence or presence of 













Figure 3.3: Perforin and Annexin/PI staining of the NK and CD8 T cells and of the PC-3 and LNCaP cells 
respectively. a) Perforin staining of the NK and CD8 T cells: The perforin expression by NK and CD8 T 
cells in the coculture models of non-adherent PBMCs and PC-3 cells, in the presence of a panel of 
therapeutic Th1 cytokines is shown. b) Annexin/PI staining of the PC-3 and LNCaP cells. The percentage 
expression of Annexin+ and PI+ PC-3 or LNCaP cells is shown, when the cells were cocultured with non-
adherent PBMCs in the presence of the Th1 therapeutic cytokines (10ng/ml IL-2, 25ng/ml IFNγ, 
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Figure 3.4: T regulatory cell (CD4+ CD25+ FoxP3+) expansion in cocultures of non-adherent PBMCs and 
PCa cells. Non-adherent PBMCs were cultured either alone (PBS) or in the presence of PC-3 or LNCaP 
cells, in the presence or absence of a panel of therapeutic Th1 cytokines (10ng/ml IL-2, 25ng/ml IFNγ, 




















In a separate study from our group, Ms Fiona Watkinson, cultured non-adherent PBMCs in 
the presence of varying IL-15 concentrations (0.1-100 ng/ml), and investigated at which IL-15 
concentration NK cells were expanding the most. She demonstrated that IL-15 induces the 
highest NK cell expansion at a concentration of 2.5ng/ml and at higher concentrations NK 
cells show a decreased expansion (n=5, *= P<0.05, **= P<0.005, ***=P<0.0005 and 













Figure 3.5: NK cell (CD56+ CD3-) expansion in response to different concentrations of IL-15. The 
expansion of NK cells at varying concentrations of IL-15 is shown, when non-adherent PBMCs were 
cultured alone (n=5, *= P<0.05, **= P<0.005, ***=P<0.0005 and ****=P<0.0001, 1-way ANOVA).  
 
In pre-existing literature however, different E:T ratios have been used (Marten, Renoth et al. 
2001, Balsamo, Vermi et al. 2012, Shi, Fan et al. 2014), therefore a critical step before 
progressing further with experiments, was to investigate which E:T ratio would produce the 
greatest expansion of NK, NKT and CD8 T cells,  and which would enhance their cytotoxicity 













N K  IL -1 5  c e llu la r  e x p a n s io n






























3.2.1 Optimisation of the immune effector cell- target cell ratio in the allogeneic 
coculture model to obtain maximum NK, NKT and CD8 T cell expansion.  
In order to optimise the allogeneic coculture’s E:T ratio, non-adherent PBMCs were 
isolated and cultured either alone or cocultured with the PC-3 cell line at 8:1, 4:1 and 2:1 
ratios in the presence or absence of IL-2, IFNγ, IL-12, IL-15 and IL-21 at their ED50 doses. 7 
days after incubation, the non-adherent PBMCs were fluorescently labelled for the markers 
CD56, CD3, CD8, perforin (protein expressed in the cytotoxic granules released by NK and 
CD8+ T cells) and CD107a (marker for degranulation of NK and CD8+ T cells).  
Figure 3.6 shows the FACS dotplots and the gating strategy when non-adherent PBMCs were 
cocultured with PC-3 cells, either in the absence of cytokines (control) or in the presence of 
10ng/ml IL-2 or 2.5ng/ml IL-15. As shown, in the presence of IL-15, NK and NKT cells expand 
more, when compared to control or IL-2.  
 
Figure 3.6: Gating strategy followed when non-adherent PBMCs were cocultured with PC-3 cells. The 
top panel dotplots show the gating of lymphocytes using forward and side scatter. The bottom panel 
shows the NK (CD56+ CD3-) and NKT (CD56+ CD3+) cell gating from the lymphocyte population, when 
non-adherent PBMCs were cocultured with PC-3 cells either alone or in the presence of 10ng/ml IL-2 
or 2.5ng/ml IL-15.  
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Figure 3.7a-c shows the NK cell expansion, as measured by CD56+ CD3- cell expression at the 
different E:T coculture ratios; Figure 3.8d-f shows the perforin expression by NK cells and 
Figure 3.9g-i shows the CD107a+ expression by NK cells.  
NK cells were highly expanded in the presence of IL-15, compared to control and the other 
Th1 cytokines, when non-adherent PBMCs were cultured alone, however in cocultures with 
PC-3 cells at 8:1 and 4:1 E:T ratios the expansion of NK cells by IL-15 was even greater. 
Perforin  and CD107a expressions by NK cells were also higher in the presence of IL-15 
compared to control or the other cytokines, at 8:1 and 4:1 E:T ratios in regards to perforin 
and at 8:1 in regards to CD107a (n=5, *p<0.05, **p<0.01, 1-way ANOVA). The cytokines IL-2, 




Figure 3.7: NK cell expansion at different coculture ratios of non-adherent PBMCs and PC-3 cells.  The 
expansion of NK cells is shown, as measured by CD56+ CD3- cell expression, in the presence or 
absence of a panel of therapeutic cytokines (IL-2 10ng/ml; 2.5ng/ml IFNγ; 2.5ng/ml IL-12; 2.5ng/ml IL-
15; 2.5ng/ml IL-21), when non-adherent PBMCs were cultured alone or in the presence of PC-3 cell 




Figure 3.8:  Perforin expression by NK cells at different coculture ratios of non-adherent PBMCs and PC-
3 cells. The perforin expression by NK cells in the presence or absence of a panel of therapeutic 
cytokines (IL-2 10ng/ml; 2.5ng/ml IFNγ; 2.5ng/ml IL-12; 2.5ng/ml IL-15; 2.5ng/ml IL-21) is shown, 
when non-adherent PBMCs were cultured alone or in the presence of PC-3 cell line at d) 8:1, e) 4:1 





Figure 3.9:  CD107a expression by NK cells at different coculture ratios of non-adherent PBMCs and PC-
3 cells.  The CD107a+ expression by NK cells is shown, in the presence or absence of a panel of 
therapeutic cytokines (IL-2 10ng/ml; 2.5ng/ml IFNγ; 2.5ng/ml IL-12; 2.5ng/ml IL-15; 2.5ng/ml IL-21), 
when non-adherent PBMCs were cultured alone or in the presence of PC-3 cell line at g) 8:1, h) 4:1 






Figures 3.10-3.12 show the NKT cell expansion, perforin and CD107a expression by 
NKT cells.  
The presence of IL-15 highly expanded the NKT cells, as observed by CD56+ CD3+ cell 
expression, when the non-adherent PBMCs were cultured alone or in the presence of PC-3 
cell line at all E:T ratios (n=5, **p<0.01, ***p<0.001, 1-way ANOVA). No other cytokine 
expanded the NKT cells. Perforin and CD107a expression by NKT cells were also increased in 
the presence of IL-15, compared to control or the other cytokines, however only when the 
PBMCs were cultured alone (n=5, *p <0.05, **p<0.01, ***p<0.001, 1-way ANOVA). In the 
presence of the PC-3 cell line, the perforin and CD107 expressions by NKT cells were not 








Figure 3.10: NKT cell expansion at different coculture ratios of non-adherent PBMCs and PC-3 cells. The 
expansion of NKT cells is shown, as measured by CD56+ CD3+ cell expression, in the presence or 
absence of a panel of therapeutic cytokines (IL-2 10ng/ml; 2.5ng/ml IFNγ; 2.5ng/ml IL-12; 2.5ng/ml IL-
15; 2.5ng/ml IL-21), when non-adherent PBMCs were cultured alone or in the presence of PC-3 cell 





Figure 3.11:  Perforin expression by NKT cells at different coculture ratios of non-adherent PBMCs and 
PC-3 cells.  The perforin expression by NKT cells is shown, in the presence or absence of a panel of 
therapeutic cytokines (IL-2 10ng/ml; 2.5ng/ml IFNγ; 2.5ng/ml IL-12; 2.5ng/ml IL-15; 2.5ng/ml IL-21), 
when non-adherent PBMCs were cultured alone or in the presence of PC-3 cell line at d) 8:1, e) 4:1 





Figure 3.12:  CD107a expression by NKT cells at different coculture ratios of non-adherent PBMCs and 
PC-3 cells The CD107a+ expression by NKT cells is shown, in the presence or absence of a panel of 
therapeutic cytokines (IL-2 10ng/ml; 2.5ng/ml IFNγ; 2.5ng/ml IL-12; 2.5ng/ml IL-15; 2.5ng/ml IL-21), 
when non-adherent PBMCs were cultured alone or in the presence of PC-3 cell line at g) 8:1, h) 4:1 






Figures 3.13-3.15a-i show the CD8+ T cell expansion and their corresponding perforin and 
CD107a expression. CD8 T cells are expanded in the presence of IL-15, when non-adherent 
PBMCs are cultured alone, however no significant difference was observed in the cocultures 









Figure 3.13: CD8 T cell expansion at different coculture ratios of non-adherent PBMCs and PC-3 cells. 
The expansion of CD3+ CD8+ T cells is shown, in the presence or absence of a panel of therapeutic 
cytokines (IL-2 10ng/ml; 2.5ng/ml IFNγ; 2.5ng/ml IL-12; 2.5ng/ml IL-15; 2.5ng/ml IL-21), when non-
adherent PBMCs were cultured alone or in the presence of PC-3 cell line at a) 8:1, b) 4:1 and c) 2:1 E:T 




Figure 3.14: Perforin expression by CD8 T cells at different coculture ratios of non-adherent PBMCs and 
PC-3 cells. The perforin expression by CD3+ CD8+ T cells is shown, in the presence or absence of a 
panel of therapeutic cytokines (IL-2 10ng/ml; 2.5ng/ml IFNγ; 2.5ng/ml IL-12; 2.5ng/ml IL-15; 2.5ng/ml 
IL-21), when non-adherent PBMCs were cultured alone or in the presence of PC-3 cell line at d) 8:1, e) 





Figure 3.15: CD107a expression by CD8 T cells at different coculture ratios of non-adherent PBMCs and 
PC-3 cells. The CD107a+ expression by CD3+ CD8+ T cells is shown, in the presence or absence of a 
panel of therapeutic cytokines (IL-2 10ng/ml; 2.5ng/ml IFNγ; 2.5ng/ml IL-12; 2.5ng/ml IL-15; 2.5ng/ml 
IL-21), when non-adherent PBMCs were cultured alone or in the presence of PC-3 cell line at g) 8:1, h) 






The same set of experiments was repeated with the LNCaP cell line. Similar results were 
obtained as in the cocultures with PC-3 cells, hence only six representative figures (Figure 
3.16a-f) are shown, where NK and NKT cell expansion is presented.  
NK and NKT cells were highly expanded in the presence of IL-15, when non-adherent PBMCs 
were cultured alone, when compared to control and the other Th1 cytokines. Additionally, 
the presence of LNCaP cells further increased the NK cell expansion at all coculture ratios in 
the presence of IL-15, when compared to control and the other cytokines (n=5, **p<0.01, 
***p<0.001, ****p<0.0001, 1-way ANOVA); no other cytokine produced an effect on the NK 
and NKT cell expansion. Perforin and CD107a expression by NK cells was also highly increased 
by the presence of IL-15, when non-adherent PBMCs were cultured alone, as well as in 
cocultures with LNCaP cells (data not shown). CD8 T cells were significantly expanded by IL-
15 when non-adherent PBMCs were cultured alone, when compared to control or the other 
cytokines, however in cocultures with LNCaP cells a trend of an increase on CD8 T cell 










Figure 3.16: NK cell expansion at different coculture ratios of non-adherent PBMCs and LNCaP cells. The 
expansion of NK cells, as measured by CD56+ CD3- cell expression is shown, in the presence or 
absence of a panel of therapeutic cytokines (IL-2 10ng/ml; 2.5ng/ml IFNγ; 2.5ng/ml IL-12; 2.5ng/ml IL-
15; 2.5ng/ml IL-21), when non-adherent PBMCs were cultured alone or in the presence of LNCaP cell 




Figure 3.17: NKT cell expansion at different coculture ratios of non-adherent PBMCs and LNCaP cells. 
The expansion of NKT cells is shown, as measured by CD56+ CD3+ cell expression, in the presence or 
absence of a panel of therapeutic cytokines (IL-2 10ng/ml; 2.5ng/ml IFNγ; 2.5ng/ml IL-12; 2.5ng/ml IL-
15; 2.5ng/ml IL-21), when non-adherent PBMCs were cultured alone or in the presence of LNCaP cell 





3.2.2 Optimisation of the immune effector cell- target cell ratio on the allogeneic 
coculture model to obtain maximum PCa cell cytotoxicity by NK, NKT and CD8 T 
cells. 
In order to assess the induction of the PCa cell apoptosis and necrosis by the non-
adherent PBMCs and in order to observe whether the presence of IL-2 and IL-15 cytokines 
has any effect on the PCa cell death and at which E:T ratios and cytokine concentrations this 
occurred, we cultured PCa cells (PC-3 or LNCaP) at a concentration of 1x105 cells/ml in a 24 
well plate overnight. The following day, non-adherent PBMCs were added at E:T ratios of 
20:1, 10:1, 8:1, 4:1, 2:1, 1:1 or 0.5:1 in the absence or presence of IL-2 (1 or 10ng/ml) or of 
various concentrations of IL-15 (0.5, 1, 2.5, 10 or 25ng/ml).  
The addition of 600μM H2O2 to one well of the plate containing PCa cells acted as a positive 
control. H2O2 has been previously found to induce cell apoptosis and necrosis and according 
to the study by Kim et al. 2003, who investigated the mechanism of H2O2 in inducing cell 
death in a human retinal pigment epithelial cell line (ARPE-19), H2O2 at a concentration of 
600μM causes the maximum induced cell death (Kim, Chung et al. 2003).  
The percentage cell death of the PCa cells was assessed by Annexin and PI positive cell 




where dead targets are defined as the PCa cells derived from the cocultures of immune 
effector cells with PCa cells, in the presence or absence of cytokines and spontaneous cell 
death is defined as the PCa cells that were cultured alone, in the absence of cytokines.  
 
When PC-3 cells were cocultured with non-adherent PBMCs at E:T ratio 2:1 the highest 
percentage of necrotic (PI+) and apoptotic (Annexin+)  cells was observed in the presence of 
10 and 25ng/ml IL-15, when compared to the percentage cell death observed in the presence 
of IL-2 and at 4:1 ratio in the presence of 2.5, 10 and 25ng/ml IL-15 (figure 3.18a) (n=4, 
*p<0.05, 1-way ANOVA).  When LNCaP cells were cocultured with non-adherent PBMCs at 
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E:T ratio 4:1, the highest percentage of necrotic and apoptotic cells was observed in the 
presence of 2.5ng/ml IL-15, when compared to the percentage cell death observed in the 




Figure 3.18: Annexin+ PI+ cell expression by PCa cells in varying coculture ratios of non-adherent PBMCs 
with PC-3 or LNCaP cells. a) Non- adherent PBMCs were cocultured at 2:1 and 4:1 E:T ratios with PC-3 
cells,  in the presence or absence of various concentrations of IL-2 and IL-15 b) Non- adherent PBMCs 
were cocultured at 4:1 E:T ratio with LNCaP cells,  in the presence or absence of various 








The optimal ratio of immune effector cells to the target cells that would result in the 
highest percentage PCa cell death was found to be 4:1 for cocultures with both PC-3 and 
LNCaP cell lines and at an IL-15 concentration of 25ng/ml. The next step was to test the 
efficacy of the other Th1 immunotherapeutic cytokines on killing the PCa cells in comparison 
to control and IL-15. As above the addition of 600μM H2O2 was used as a positive control. 
The percentage cell death was assessed by Annexin and PI double positive cell staining and 
the cell apoptosis and necrosis was measured using the same equation as above.  
 
Non-adherent PBMCs led to the highest cytotoxicity towards PC-3 and LNCaP cell lines in the 
presence of IL-15 (figure 3.19 a, b) (n=4, *P<0.05, 1-way ANOVA). In cocultures with PC-3 
cells, the presence of IL-12 and of IL-21 also led to an increased cytotoxicity, however that 









Figure 3.19:  Annexin+ PI+ cell expression by PCa cells when non-adherent PBMCs were cocultured with 
PC-3 or LNCaP cells at 4:1 E:T ratio. Non- adherent PBMCs were cocultured at 4:1 E:T ratio with a) PC-3 
cells or b) LNCaP cells, in the presence or absence of a panel of therapeutic Th1 cytokines (IL-2 













3.2.3 Optimisation of the immune effector cell- target cell ratio on the syngeneic 
coculture model 
Alloreactivity may be influencing the expansion of the NK and NKT in the above 
allogeneic coculture model, hence a syngeneic model was developed in order to investigate 
whether the effects seen above are due to alloreactivity. In this syngeneic system NK or T 
cells isolated from splenocytes of a murine C57BL/6 mouse were cocultured with the PCa cell 
line TRAMP-C1, also derived from a C57BL/6 mouse; in this set of experiments the first step 
was also to optimise the E:T ratio.  
 
NK cells were isolated and cocultured at varying ratios with TRAMP-C1 cells in the presence 
or absence of 2.5ng/ml IL-15. The immune effector cell expansion (NK cells: NK1.1+ CD3-; NKT 
cells: NK1.1+ CD3+) and the TRAMP-C1 cell killing (PI+ cells) by the immune effector cells was 
measured by flow cytometry.   
 
The highest percentage of TRAMP-C1 cell death was observed at 1:1, 2:1 and 4:1 E:T ratios in 
the presence of IL-15, when compared to control (no cytokine) (n=5, *p<0.05, 1-way ANOVA) 
(figure 3.20). IL-15 significantly expanded the NK cells compared to the control, as observed 
by NK1.1+ CD3- cell expression, at the 4:1 E:T ratio (n=5, *p<0.05, 1-way ANOVA)  (figure 
3.21), hence the ratio that was used on further experiments was 4:1.  
 
The TRAMP-C1 cells were also cultured in the presence or absence of IL-15, in order to verify 
whether there is any direct effect of this cytokine on PCa cell death (Figure 3.22). The 
TRAMP-C1 cell death was not significantly affected by the presence of IL-15 when compared 











Figure 3.20: PI+ cell expression by TRAMP-C1 cells when NK isolated cells were cocultured with TRAMP-
C1 cells. NK isolated cells were cocultured with TRAMP-C1 cells at different E:T ratios, in the presence 
or absence of 2.5ng/ml IL-15. The TRAMP-C1 cell number was a constant number of 1x105 cells, 
whereas the number of NK cells varied between 25x104cells -for the lowest ratio 0.25:1- and 8x105 
cells – for the highest ratio 8:1 (n=5,* P<0.05, 1-way ANOVA).  
 
 
Figure 3.21: NK cell expansion at different coculture ratios of isolated NK cells and TRAMP-C1 cells. The 
expansion of NK cells is shown, as measured by NK1.1+ CD3- cell expression; NK isolated cells were 
cocultured at different E:T ratios, in the presence or absence of 2.5ng/ml IL-15. The ratios that were 
used had variable E:T cell numbers, shown in the table 3.1 (n=5, *P<0.05, 1-way ANOVA).  
 
 

































1x105 1x105 8x105 4x105 2x105 1x105 5x104 25x104 1x105 1x105 
Table 3.1: Cell counts of effector and target cells used in each ratio of cocultures are shown. 
 
 
Figure 3.22: PI+ cell expression by TRAMP-C1 cells, when they were cultured alone. TRAMP-C1 cells  
were cultured at varying cell concentrations in the presence or absence (control- no cytokine) of 










3.2.4 Screening of Th1 cytokines in the in vitro syngeneic immune effector cell – 
target cell coculture model 
NK or T enriched cells from C57BL/6 mouse splenocytes were cocultured in the 
presence or absence of the TRAMP-C1 PCa cell line, derived from the C57BL/6 mouse 
prostate cancer, at a 4:1 E:T ratio, in the presence or absence of a panel of murine Th1 
therapeutic cytokines (10ng/ml IL-2, 2.5ng/ml IFNγ , 2.5ng/ml IL-12, 2.5ng/ml IL-15, 2.5ng/ml 
IL-21).  
 
IL-15 is the only cytokine which highly expands the NK (NK1.1+CD3-) and NKT (NK1.1+ CD3+) 
cells, compared to the control, IL-2, IFNγ, IL-12 and IL-21 cytokines, when enriched NK cells 
from splenocytes are cultured alone (data not shown). Furthermore, in cocultures with 
TRAMP-C1 cells, IL-15 expands the NK and NKT cells even more, compared to when NK cells 
were cultured on their own and compared to control and the other cytokines. When T 
enriched cells were cocultured with TRAMP-C1 cells with or without cytokines, the presence 
of IL-15 highly expanded the CD8 T cells (CD8+ CD4-) (Figure 3.23a-c) (n=5, *p<0.05, 
**p<0.01, ***p<0.001, 1-way ANOVA). T regulatory cell (CD4+ CD25+ FoxP3+) expression is 
not affected by IL-15, neither in the allogeneic coculture model as shown in the preliminary 
results (figure 3.4), nor in the syngeneic coculture system (Figure 3.24). Surprisingly, IL-2 does 
not have any effect on the Treg expression, when T enriched cells were cocultured with 




Figure 3.23: NK, NKT and CD8 T cell expansion when NK- or T- enriched cells were cocultured with 
TRAMP-C1 cells.  The expansion of a) NK cells (NK1.1+ CD3-), b) NKT cells  (NK1.1+ CD3+), c) CD8 T cells 
(CD8+ CD4-) in the presence or absence of a panel of therapeutic cytokines (IL-2 10ng/ml; 2.5ng/ml 
IFNγ; 2.5ng/ml IL-12; 2.5ng/ml IL-15; 2.5ng/ml IL-21) is shown, when NK-enriched or T- enriched cells 
were cultured in the presence of TRAMP-C1 cell line at 4:1 E:T ratio (n=5, *p<0.05, **p<0.01, 






Figure 3.24: Treg cell expansion when T-enriched cells were cocultured with TRAMP-C1 cells. The 
expansion of Treg cells is shown, when T enriched cells were cocultured with the TRAMP-C1 cell line, 
in the presence or absence of a panel of therapeutic Th1 cytokines (10ng/ml IL-2, 2.5ng/ml IFNγ , 





















An in vitro allogeneic coculture model of immune effector cells and PCa cell lines was 
established in our laboratory. This coculture model mimics the PCa microenvironment and it 
has enabled us to study the effects of a panel of therapeutic Th1 cytokines (e.g. IL-2, IL-12, IL-
15) on the immune effector cell proliferation and activity.  
 
In preliminary data from our lab we have established an allogeneic model in which 
non-adherent PBMCs were cocultured in the presence or absence of either PC-3 or LNCaP 
cell lines in the presence or absence of a panel of therapeutic Th1 cytokines. It was found 
that IL-15 is the only cytokine that increases significantly the expansion of NK, NKT and CD8 T 
cells when compared to control (no cytokine) or to the other cytokines and when non-
adherent PBMCs were cultured alone. The effects of IL-15, aiding the function and expansion 
of NK cells have been previously studied and established in literature (Carson, Giri et al. 1994, 
Huntington, Legrand et al. 2009) . However, in our coculture model, it was observed that in 
the presence of the PCa cell lines, IL-15 increased the expansion of the immune effectors 
cells, NK, NKT and CD8 T cells to a greater extent than when lymphocytes are cultured alone.  
Additionally, IL-15 aided the killing of PCa cells by the immune effector cells, unlike any other 
cytokine and this was observed both from an annexin and PI surface staining on the PCa cell 
lines, as well as from the upregulation of markers of cytotoxicity (e.g. Perforin, CD107a) 
(Elhage, Galustian et al. 2011).  
 
The first aim of this chapter was to verify whether the effector to target (E:T) 
coculture ratio that was used in the preliminary experiments, 8:1, was optimal for the 
greatest expansion of NK, NKT and CD8 T cells, with a concomitant enhancement of the PCa 
cytotoxicity by these immune effector cells, as various E:T ratios have been used in literature 
previously (Marten, Renoth et al. 2001, Balsamo, Vermi et al. 2012).  
 
A panel of varying coculture E:T ratios were investigated for the best expansion of immune 
effector cells and their cytotoxicity towards the PCa cell lines. It was found that the highest 
cell killing by these immune effector cells towards the PC-3 cell line was induced at a 4:1 or 
2:1 ratio and in the presence of 2.5ng/ml of IL-15; in the cocultures with the LNCaP cell line, 
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the highest percentage cell killing as measured by Annexin and PI (markers for apoptosis and 
necrosis respectively) surface staining, was observed at a 4:1 ratio and 2.5ng/ml of IL-15. 
At the 8:1, 4:1 and 2:1 ratios, the presence of IL-15- at a concentration of 2.5ng/ml- highly 
expanded the NK and NKT cells, their perforin and CD107a expression in cocultures with both 
PCa cell lines. Taking these results together and since the highest percentage killing of LNCaP 
cells in the presence of IL-15, was produced at a 4:1 E:T ratio only, it was decided that the 
optimal E:T coculture ratio for the allogeneic system is 4:1 and this would be used in further 
experiments.  
 
When non-adherent PBMCs were cultured on their own, the presence of IL-15 highly 
expanded NK, NKT and CD8 T cells, as shown in the preliminary results as well. However it 
was shown that in the presence of PCa cells, the IL-15 mediated expansion of NK and NKT 
cells was even higher.  
CD8 T cells did not seem to significantly expand in the cocultures of non-adherent PBMCs 
with PCa cells in the presence of IL-15, when compared to control; this result is not in 
agreement with the preliminary data shown in figure 3.2. However, the concentration of IL-
15 that was used in the preliminary experiment was 25ng/ml, whereas in further experiments 
that were done 2.5ng/ml of IL-15 were used, a concentration which was shown to induce the 
maximum NK cell expansion (figure 3.5). 
 
The coculture model that was used for the preliminary work and for the optimisation 
experiments was an allogeneic coculture model (ie. Peripheral blood mononuclear cells are 
not derived from the same donor as the PCa cells), so it could be argued that alloreactivity 
may be promoting expansion of the NK and NKT cells in the presence of IL-15. Therefore, 
another aim of this study, was to create a syngeneic murine in vitro coculture model, in which 
murine NK or T cells purified from splenocytes of C57BL/6 mice, were cocultured with the 
TRAMP-C1 cell line, a PCa cell line also derived from transgenic adenocarcinoma of the 
C57BL/6 mouse prostate.  
The presence of IL-15 in the cocultures, produced a highly significant increase in the killing of 
the TRAMP-C1 cells by the NK cells, as observed by the PI+ cell expression, compared to the 
control (no cytokine), at E:T ratios of 1:1, 2:1 and 4:1. However the most significant increase 
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in the expansion of NK1.1+ NK cells, was observed at an E:T ratio of 4:1. Based on this, it was 
decided that the optimal ratio that would be used for further experiments was 4:1.  
 
Taking into account the observations so far, it is understood that the presence of IL-
15 in cocultures of immune effector cells with PCa cell lines, enhances the expansion of the 
immune effector cells and their cytotoxic activity towards the PCa cell lines. However, the 
direct effect of IL-15 on the PCa cell lines, was not investigated; therefore in order to examine 
whether IL-15 plays any role on the TRAMP-C1 cell death, TRAMP-C1 cells were cultured 
alone, in the presence or absence (control) of IL-15 and at different cell concentrations.  
As seen in figure 3.22, 5-15% of TRAMP-C1 cells seem to be necrotic and the percentage cell 
death is proportional to the amount of cells that are added per well; the higher the cell 
concentration in a well, the higher the cell death. Nevertheless, the presence of IL-15 does 
not seem to have any effect on the TRAMP-C1 cell death, when compared to the control, 
hence it is concluded that IL-15 is only affecting and modulating the NK and the T cell 
function in the coculture models. Unfortunately, a drawback in the cell killing experiments on 
the syngeneic coculture model, was the absence of a positive control; on the allogeneic 
coculture models H2O2 was added on the PCa cell lines (PC-3 and LNCaP), to observe the 
maximum percentage necrosis of the PCa cells. In future, these experiments should be 
repeated with the addition of a positive control.   
  
In order to investigate whether a panel of Th1 therapeutic cytokines, that were also 
used in our allogeneic models, had any effect on the expansion and activity of NK and T 
purified cells in the syngeneic model, we cocultured NK enriched cells and T enriched cells in 
the presence or absence of TRAMP-C1 cells, and in the presence or absence of each of the 
cytokines.  It was observed that IL-15 is the most potent activator of NK, NKT and CD8 T cells 
either in the presence or absence of TRAMP-C1 cells, when compared to the control or to the 
other Th1 cytokines. These results are in agreement with those from the allogeneic coculture 
model, meaning that alloreactivity does not have any effect on the results we are observing.  
Unfortunately, the perforin and CD107a expression by the NK, NKT and CD8 T cells was not 
examined in the syngeneic coculture system, which should also be done in the future, in 
order to observe whether the presence of IL-15 in cocultures also has an effect on the 




To conclude, IL-15 has been previously shown to enhance NK and T cell proliferation 
(Fehniger, Suzuki et al. 2001) (Gravisaco, Mongini et al. 2003, Sato, Sabzevari et al. 2011) . 
However, to our knowledge we are the first group in the UK, to show that IL-15 is also active 
























Studies of the mechanism of action of IL-15 on NK and NKT cells- 

















In parallel to this work, Mr Oussama Elhage from the Protein Therapeutics Laboratory, 
investigated whether the enhanced cytotoxicity of the non-adherent PBMCs towards the PCa 
cell lines in the presence of IL-15, was attributed to NK or CD8 T cells. He did that by 
depleting CD56+ cells (NK and NKT cells) and CD8+ T cells in the allogeneic coculture model, 
and then examining the IL-15 mediated effector cell induced PCa cell killing and expansion of 
CD8+ and CD56+ cells respectively, within the cocultures. 
It was observed that the depletion of CD8 T cells does not affect the CD56+ (NK) cell 
expansion and that CD56+ cell depletion does not affect the CD8 T cell expansion, when 
compared to the non-depleted cells, both in the presence and absence of IL-15 (n=5, 
*p<0.05, 1-way ANOVA) (Figure 4.1a,b). Additionally, it was observed that when CD8 T cells 
were depleted, the presence of IL-15 enhanced the CD56+ (NK) cytotoxicity towards the PC-3 
cells, as observed by the dead to live PC-3 cells ratio, when compared to the control (n=5, 
*p<0.05, 1-way ANOVA) (Figure 4.1c). When CD56+ cells were depleted, the percentage of 
dead to live PC-3 cells, was similar in the control and in the presence of IL-15, meaning that 
IL-15 dependent PC-3 cell cytotoxicity may be attributed to the NK cells and not the CD8 T 
cells. The NKT cells’ effect was not examined, hence it cannot be excluded that NKT cells also 


















Figure 4.1: CD56 and CD8 cell depletions: expansion and cell killing assay a) Expansion of NK cells as 
measured by the CD56+ CD3- expression, when non-adherent PBMCs or CD8 T-depleted cells were 
cocultured with PC-3 cells in the presence or absence of IL-15. b) Expansion of CD8+ T cells, when non-
adherent PBMCs or CD56+ depleted cells were cocultured with PC-3 cells, in the presence or absence 
of IL-15 (n=5, *p<0.05, 1-way ANOVA). c) Dead to live PC-3 cells ratio shown, when non-adherent 
PBMCs, CD8 T-depleted cells or CD56 - depleted cells were cocultured with PC-3 cells in the presence 
or absence (control) of IL-15 (n=5, *p<0.05, 1-way ANOVA). 
 
NK cells have the ability to distinguish transformed cells from healthy cells, via the 
receptors that they bear on their surface. These are either inhibitory (iNKRs) or activatory 
receptors (aNKRs) that regulate the killing of the target cells; the iNKRs recognise molecules 
of the Major Histocompatibility Complex-I (MHC-I) and in humans these are called Killer 
Immunoglobulin- like Receptors (KIR). Tumour cells express low levels of MHC-I molecules, 
hence they often escape the NK cell recognition through this inhibitory signalling (Bottino, 
Castriconi et al. 2005). In order for NK cells to be able to distinguish the cancer cells, they rely 
on stimulatory signals that are delivered via the aNKRs; these directly trigger the NK cell to kill 
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its target by the release of cytokines (e.g. IFNγ) and through the release of cytotoxic granules, 
which are stored within secretory lysosomes (Topham and Hewitt 2009). (More info on NKRs 
can be found on sections 1.2.2.1 and 1.2.3 in this thesis). 
 
Following these observations, we wanted to determine whether IL-15 was modulating 
the expression of activatory or inhibitory NK receptors (or their ligands) on NK cells. IL-15 has 
been previously shown to have an effect on the expression of the activatory NKR NKG2D on 
NK cells (Sutherland, Chalupny et al. 2002, Muntasell, Magri et al. 2010), but its effects on 
this and other receptors have not been studied when effector cells are cultured with tumour 
cell lines, and particularly, PCa cell lines. 
The aim of this part of the project was to investigate the mechanism/s by which IL-15 acts on 
effector cell mediated killing of PCa cells in the allogeneic coculture model, focusing on IL-15-
mediated effects on NK cells. The NKRs and their corresponding ligands were studied in 
detail, in order to investigate whether IL-15 modulates the expression and shedding of these 
ligands. 
 
A panel of various receptors was assessed in the presence or absence of IL-2 and IL-15 
cytokines, in our in vitro allogeneic coculture model of non-adherent PBMCs and PC-3 or 
LNCaP cell lines. The ratio of cells that was used, was 4:1 PBMCs:PCa cells, as optimised on 
the previous chapter. The NKRs chosen for investigation have been found to play roles in 
immunosurveillance in previous literature (discussed further on sections 1.2.2.1 and 1.2.3) 
and antibodies to these were commercially available at the time that these experiments were 
done. The iNKRs that were studied were the Killer Immunoglobulin-like receptors (KIRs) 
KIR2DL1, KIR3DL1 and KIR2DL2. The aNKRs that were studied were: NKG2D, NKp30, NKp44, 










4.2.1 Effects of IL-2 and IL-15 cytokines on KIR family and on activatory receptor 
expression by NK cells 
 
In order to investigate the effects of IL-2 and IL-15 on both the inhibitory and activatory 
NKRs, non-adherent PBMCs were cultured either alone, or in the presence of low or high 
dose of IL-2, or in the presence of IL-15 or IL-15 and a low dose of IL-2. The low dose of IL-2 
(1ng/ml) is normally found in human physiological processes, whereas the high dose 
(10ng/ml) could enhance the anti-tumour activity, as high doses of IL-2 are currently used in 
the treatment of melanoma and RCC as described in section 1.4. 
 
In the presence of IL-15, the expression of the iNKR KIR2DL2 by the NK cells was highly 
upregulated, unlike in the presence of IL-2, where none of the receptors’ expression was 
affected  (n=12, **p<0.01, 1-way ANOVA) (Figure 4.2a-c). In addition, in the presence of IL-15 
the expression of the natural cytotoxicity receptor (NCRs) NKp46 was significantly 
upregulated (n=12, *p<0.05, 1-way ANOVA) (Figure 4.3 d-f) as well as that of the aNKR 






Figure 4.2 a-c: Expression of KIR2DL1, KIR2DL2 and KIR3DL1 by NK cells. Non-adherent PBMCs were 
cultured in the presence or absence of IL-2 (1 or 10ng/ml) and of IL-15 (2.5ng/ml) with or without IL-2 







Figure 4.3 d-f: Expression of NCRs – NKp30, NKp44, NKp46 - by NK cells. Non-adherent PBMCs were 
cultured in the presence or absence of IL-2 (1 or 10ng/ml) and of IL-15 (2.5ng/ml) with or without IL-2 






Figure 4.4 g,h: Expression of DNAM-1 and NKG2D by NK cells. Non-adherent PBMCs were cultured in 
the presence or absence of IL-2 (1 or 10ng/ml) and of IL-15 (2.5ng/ml) with or without IL-2 (1ng/ml) 










4.2.2 Effects of IL-2 and IL-15 cytokines on the KIR family and on activatory  
receptor expression by NK cells in the coculture models of non-adherent PBMCs 
and PC-3 or LNCaP cell lines. 
 
The next aim was to investigate the effects of IL-2 and IL-15 on both the inhibitory 
and activatory NKRs when non-adherent PBMCs were cocultured with PC-3 or LNCaP cell 
lines, either alone, or in the presence of low or high dose of IL-2, or in the presence of IL-15 
or IL-15 and a low dose of IL-2. 
For all the coculture model experiments, the E:T ratio used was 4:1, as optimised on chapter 
3. 
In the cocultures of non-adherent PBMCs with PC-3 cells, in the presence of IL-15 the 
expression of NKG2D aNKR was significantly upregulated when compared to control and IL-2 
(Figure 4.5-4.7a-h) (n=7, *p<0.05, 1-way ANOVA). The presence of IL-2 or IL-15 did not affect 







Figure 4.5 a-c: Expression of KIR2DL1, KIR2DL2 and KIR3DL1 by NK cells in cocultures with PC-3 cells. 
Non-adherent PBMCs were cocultured with PC-3 cells in the presence or absence of IL-2 (1 or 






Figure 4.6 d-f: Expression of NCRs – NKp30, NKp44, NKp46 - by NK cells in cocultures with PC-3 cells. 
Non-adherent PBMCs were cocultured with PC-3 cells in the presence or absence of IL-2 (1 or 





Figure 4.7 g,h: Expression of DNAM-1 and NKG2D by NK cells in cocultures with PC-3 cells. Non-
adherent PBMCs were cocultured with PC-3 cells in the presence or absence of IL-2 (1 or 10ng/ml) 











In the cocultures of non-adherent PBMCs with LNCaP cells (figures 4.8- 4.10), in the presence 
of IL-2 and of IL-15 the expression of DNAM-1 was upregulated. The presence of IL-15 
however, additionally upregulated the expression of KIR2DL2 and downregulated the NKp30 
expression (n=5, *p<0.05, **p<0.01, 1-way ANOVA). 
 
Figure 4.8 a-c: Expression of KIR2DL1, KIR2DL2 and KIR3DL1 by NK cells in cocultures with LNCaP cells. 
Non-adherent PBMCs were cocultured with LNCaP cells in the presence or absence of IL-2 (1 or 





Figure 4.9 d-f: Expression of NCRs – NKp30, NKp44, NKp46 - by NK cells in cocultures with LNCaP cells. 
Non-adherent PBMCs were cocultured with LNCaP cells in the presence or absence of IL-2 (1 or 





Figure 4.10 g,h: Expression of DNAM-1 and NKG2D by NK cells in cocultures with LNCaP cells. Non-
adherent PBMCs were cocultured with LNCaP cells in the presence or absence of IL-2 (1 or 10ng/ml) 












4.2.3 Effects of IL-2 and IL-15 cytokines on ligand expression by the PCa cell lines, 
PC-3 and LNCaP cultured alone and in the allogeneic coculture model 
 
A panel of NK cell receptor ligands expressed by PCa cells corresponding to the NK cell 
receptors was investigated in this study. The ligands that were studied included those of the 
NKG2D aNKR, MICA, MICA/B and ULBP1, the ligand Nectin-2 which is a ligand for the aNKR 
DNAM-1, the HLA-A,B,C ligand, recognised by T cell receptor interactions and lastly HLA-I 
Bw4, which is recognised by the KIR3DL1 iNKR. 
For some of the receptors that were investigated in section 4.2.2-4.2.3 their ligands are 
unknown or antibodies were not commercially available, hence the ones described here were 
studied. 
 
In order to investigate the expression of the ligands by the PCa cell lines, PC-3 and 
LNCaP cells were cultured on their own, in the absence of any cytokine or in the presence of 
low (1ng/ml) or high dose (10ng/ml) of IL-2 or in the presence of IL-15 (2.5ng/ml) with or 
without IL-2 (1ng/ml). No significant difference was observed in any of the ligands expressed 
by the PCa cell lines, in the presence of IL-15 and/or IL-2 cytokines, when compared to the 
















When the ligand expression by PC-3 cells was investigated in the cocultures with non-
adherent PBMCs, a significant downregulation of the ULBP1 NK ligand was observed, in the 




Figure 4.11: Expression of ULBP1 by PC-3 cells in cocultures with PBMCs. PC-3 cells were cocultured 
with non-adherent PBMCs cells in the presence or absence of IL-2 (1 or 10ng/ml) and of IL-15 

















When investigating the ligand expression by the LNCaP cell line when coculturing with non-
adherent PBMCs in the presence or absence of IL-2 and IL-15 cytokines, it was observed that 
the presence of IL-15 significantly downregulated the expression of the ligands MICA, ULBP1, 
Nectin-2 and HLA-I Bw4 (n=4, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, 1-way ANOVA) 




Figure 4.12 a,b: Expression of MICA and ULBP1 by LNCaP cells in cocultures with PBMCs. LNCaP cells 
were cocultured with non-adherent PBMCs cells in the presence or absence of IL-2 (1 or 10ng/ml) and 






Figure 4.13 c,d: Expression of Nectin-2 and HLA Class I Bw4 by LNCaP cells in cocultures with PBMCs. 
LNCaP cells were cocultured with non-adherent PBMCs cells in the presence or absence of IL-2 (1 or 
10ng/ml) and of IL-15 (2.5ng/ml) with or without IL-2 (1ng/ml) (n=4, *p<0.05, **p<0.01, ***p<0.001, 










4.2.4 Soluble expression of the Nectin-2 and MICA tumour cell ligands in the 
supernatants of the cocultured PCa/NK cells 
In order to determine whether the downregulated expression of the above ligands 
(MICA, Nectin-2) in the presence of non-adherent PBMCs and IL-15 was due to increased 
ligand shedding, supernatants were collected from the allogeneic coculture model of non-
adherent PBMCs with both PC-3 and LNCaP cell lines, in the presence or absence of the 
PBMCs, in the presence or absence of IL-15 and/or IL-2 cytokines. The supernatants were 
then tested by ELISA for the presence of MICA, ULBP1 and Nectin-2. Shedding of MICA and 
Nectin 2 was also investigated in cocultures of PC-3 cells with non-adherent PBMCs although 























There was no ULBP1 expressed in the supernatants of cocultures of PC-3 or LNCaP with non-
adherent PBMCs, with or without cytokines; hence their results are not mentioned here. 
The MICA and Nectin-2 ELISA standard curves are shown in figure 4.14 for the supernatants 






Figure 4.14: Standard curves of the MICA and Nectin-2 ELISAs. ELISAs were performed for the 
detection of MICA and Nectin-2 expression in the supernatants of cocultures of non-adherent PBMCs 






y = 0.0003x + 0.1613 






















MICA concentration (pg/ml) 
y = 0.0027x + 0.2563 




















Nectin-2 concentration (pg/ml) 
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Interestingly, there was a significant decrease observed in the soluble expression of MICA in 
the presence of IL-2 in the cocultures of non-adherent PBMCs and PC-3 cells. However, the 
decrease was much greater in the presence of IL-15 (n=7, **p<0.01, ****p<0.0001, 1-way 
ANOVA). Culturing PC-3 cells alone, with or without cytokines, did not affect expression of 
the soluble MICA (Figure 4.15). 
No significant difference was observed in the Nectin-2 expression, neither in the cocultures 
with non-adherent PBMCs, nor in the PC-3 cells alone.  The concentration of Nectin-2 in the 
supernatants of PC-3 cells when cultured alone, was lower than that in the cocultures with 





Figure 4.15: MICA and Nectin-2 soluble expression in supernatants of cocultures of PC-3 cells with 
PBMCs. ELISAs were performed for the detection of soluble MICA or Nectin-2 in the supernatants of 
the allogeneic cocultures, with or without non-adherent PBMCs and PC-3 cell lines, with IL-2 (1 or 
10ng/ml) or IL-15 (2.5ng/ml) or without cytokines. MICA: n=7, **p<0.01, ****p<0.0001, 1-way 
ANOVA. Nectin-2: n=4, p>0.05, 1-way ANOVA. 
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The MICA and Nectin-2 ELISA standard curves are shown in figure 4.16, for which the 







Figure 4.16: Standard curves of the MICA and Nectin-2 ELISAs. ELISAs were performed for the 
detection of MICA and Nectin-2 expression in the supernatants of cocultures of non-adherent PBMCs 
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There was a highly significant decrease observed in the soluble expression of MICA in the 
presence of IL-15 in the cocultures of non-adherent PBMCs with LNCaP cells, when compared 
to control and IL-2 (n=4, ***p<0.001, 1-way ANOVA); no effect on the MICA soluble 
expression was observed when LNCaP cells were cultured alone with or without cytokines 
(Figure 4.17). 
No significant difference was observed in the Nectin-2 soluble expression, neither in the 
cocultures with non-adherent PBMCs, nor in the LNCaP cells alone (Figure 4.17).  The 
concentration of Nectin-2 in the supernatants of LNCaP cells, when cultured alone, was lower 
than that in the cocultures with PBMCs, however the difference was not significant (n=4, 






Figure 4.17: MICA and Nectin-2 soluble expression in supernatants of cocultures of LNCaP cells with 
PBMCs. ELISAs was performed for the detection of soluble MICA or Nectin-2 in the supernatants of 
the allogeneic cocultures, with or without non-adherent PBMCs and LNCaP cell lines, with IL-2 (1 or 




4.2.5 Blocking of NKG2D and MICA in the in vitro allogeneic coculture model of 
non-adherent PBMCs and PCa cell lines 
Due to the significant inhibitory effect of IL-15 on MICA shedding on PC-3 and LNCaP, 
NKG2D and its ligand, MICA, were blocked using neutralising antibodies in the in vitro 
allogeneic coculture model, in order to investigate whether NKG2D or MICA is most 
important in the NK activatory functions of IL-15. 
 
Non-adherent PBMCs were cocultured with either PC-3 or LNCaP cell lines, in the absence or 
presence of IL-2 and IL-15 cytokines, with or without neutralizing antibodies against NKG2D 
and MICA or corresponding isotype controls. The NK and NKT cell expansions were measured 
as well as the NKG2D expression. MICA was not successfully blocked in our coculture system, 
hence the results are not shown. In addition, the PCa cell killing by NK and NKT cells was 
measured by Annexin/PI staining and the supernatants were also collected to check for the 
presence of shed MICA ligand. 
 
4.2.5.1 NK and NKT cell expansion in cocultures of immune effector cells with PCa 
cell lines, in the presence of an NKG2D blocking antibody 
Non-adherent PBMCs were cultured with or without PC-3 cells, in the absence or 
presence of IL-2 and IL-15, with or without aNKG2D antibody or isotype control; figure 4.18 
shows the expansion of NK and NKT cells and the NKG2D surface expression per NK and NKT 
cell respectively. IL-15 greatly expands the NK and NKT cells, as it has been shown previously, 
even when the NKG2D receptor is blocked. However, NK cells in cocultures of non-adherent 
PBMCs and PC-3 cells are expanded more by IL-15, than NK cells in non-adherent PBMCs 
alone treated with IL-15 (n=4, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, 1-way 
ANOVA). 
 
The percentage of NKG2D receptor per NK cell was substantially increased in the presence of 
IL-15, when compared to control, when PBMCs are cultured alone (n=4, *p<0.05, 1-way 
ANOVA). Blocking NKG2D seems to be decreasing the expansion of NK cells in cocultures of 
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non-adherent PBMCs with PC-3 cells; this may be partly due to an increase in NKG2D in the 
presence of IL-15 or due to a decrease in the shed MICA.  
The expression of NKG2D in the presence of the blocking antibody was significantly lower, 
both in the presence or absence of PC-3 cells, signifying that the receptor was successfully 
blocked and that the blocking of the receptor does not affect the NK cell expansion.  
NKT cells were also substantially increased in the presence of IL-15, both in the presence and 
absence of PC-3 cells (n=4, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, 1-way ANOVA). 
The NKG2D expression by NKT cells in cocultures with PC-3 cells was significantly higher in 
the presence of IL-15, compared to that in the presence of aNKG2D (n=4, *p<0.05, 1-way 
















Figure 4.18: NKG2D blockade in cocultures of PBMCs with PC-3 cells: effects on NK cell expansion and 
NKG2D expression. NK cell expansion, as observed by CD56+ CD3- cell expression and the NKG2D 
receptor expression per NK cell are shown, when non-adherent PBMCs were cultured alone, with or 
without PC-3 cells, with or without IL-2 (10ng/ml) and IL-15 (2.5ng/ml), with or without the addition 
of aNKG2D (10μg/ml) or its corresponding IgG1 isotype control (10μg/ml) (n=4, *p<0.05, **p<0.01, 





Figure 4.19: NKG2D blockade in cocultures of PBMCs with PC-3 cells: effects on NKT cell expansion and 
NKG2D expression. NKT cell expansion, as observed by CD56+ CD3+ cell expression and the NKG2D 
receptor expression per NKT cell are shown, when non-adherent PBMCs were cultured alone, with or 
without PC-3 cells, with or without IL-2 (10ng/ml) and IL-15 (2.5ng/ml), with or without the addition 
of aNKG2D (10μg/ml) or its corresponding IgG1 isotype control (10μg/ml) (n=4, *p<0.05, **p<0.01, 










The same experiment was repeated in cocultures with LNCaP cells, as shown in figures 4.20 
and 4.21. IL-15 highly expanded the NK and NKT cells, when non-adherent PBMCs were 
cultured on their own and this expansion was even higher in cocultures with LNCaP cells 
(n=4, *p<0.05, **p<0.01, ***p<0.001, 1-way ANOVA). 
The presence of IL-15 increased the NKG2D expression by NK cells in cocultures of non-
adherent PBMCs with LNCaP cells, whereas only when the PBMCs were cultured alone, IL-15 












Figure 4.20: NKG2D blockade in cocultures of PBMCs with LNCaP cells: effects on NK cell expansion and 
NKG2D expression. The NK cell expansion, as observed by CD56+ CD3- cell expression and the NKG2D 
receptor expression per NK cell were shown, when non-adherent PBMCs were cultured alone, with or 
without LNCaP cells, with or without IL-2 (10ng/ml) and IL-15 (2.5ng/ml), with or without the addition 
of aNKG2D (10μg/ml) or its corresponding IgG1 isotype control (10μg/ml) (n=4, *p<0.05, **p<0.01, 





Figure 4.21: NKG2D blockade in cocultures of PBMCs with LNCaP cells: effects on NKT cell expansion 
and NKG2D expression. The NKT cell expansion, as observed by CD56+ CD3+ cell expression and the 
NKG2D receptor expression by these NKT cells is shown, when non-adherent PBMCs were cultured 
alone, with or without LNCaP cells, with or without IL-2 (10ng/ml) and IL-15 (2.5ng/ml), with or 
without the addition of aNKG2D (10μg/ml) or its corresponding IgG1 isotype control (10μg/ml) (n=4, 









4.2.5.2 PCa cell cytotoxicity by immune effector cells in cocultures of non-
adherent PBMCs with PCa cell lines, in the presence of an NKG2D blocking 
antibody 
The cytotoxic activity of non-adherent PBMCs towards the PCa cell lines (PC-3 and 
LNCaP) in the presence of an NKG2D blocking antibody was also assessed. In the cocultures 
of non-adherent PBMCs with LNCaP cells, with or without NKG2D blocking antibody and in 
the presence of IL-15, an increased amount of apoptotic cells was observed, by Annexin+ cell 
staining, when compared to the control or IL-2 (Figure 4.22) (n=3, **p<0.01, 1-way ANOVA). 
No significant difference was observed in the percentage of apoptotic cells with or without 
NKG2D blockade ether in the presence or absence of cytokines. Similar results were observed 
in the cocultures with PC-3 cells, hence they are not shown here. 
 
Figure 4.22: Annexin+ cell expression by LNCaP cells in cocultures with PBMCs in the presence or 
absence of aNKG2D. Non- adherent PBMCs were cocultured with LNCaP cells,  in the presence or 
absence of IL-2 (10ng/ml) and IL-15 (2.5ng/ml), in the presence or absence of aNKG2D (10μg/ml) or 






4.2.5.3 Investigation of MICA soluble expression in the supernatants of cocultures 
of non-adherent PBMCs with PCa cell lines, in the presence of and NKG2D and 
MICA blocking antibodies 
The supernatants from the cocultures of non-adherent PBMCs with PCa cell lines, 
with or without blocking antibody against NKG2D and MICA, were collected and tested by 
ELISA for the presence of soluble MICA. Even if MICA was not blocked in the phenotyping and 
cell killing experiments, the supernatants from the samples where MICA was blocked were 
still collected and tested on the ELISA. 
 
 
Figure 4.23: Standard curve of the MICA ELISA.  Soluble MICA in the supernatants of cocultures of non-
adherent PBMCs with PCa cells, in the absence or presence of IL-2 (1 or 10ng/ml) or IL-15 (2.5ng/ml) 
cytokines, in the presence or absence of blocking antibodies against MICA and NKG2D, was 










y = 0.0004x + 0.1507 


















MICA concentration (pg/ml) 
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In the cocultures of non-adherent PBMCs with PC-3 cells, the presence of IL-15 decreased the 
expression of soluble MICA (n=3, *p<0.05, **p<0.01, 1-way ANOVA), as also shown 
previously on figure 4.15; however since this was a new set of in vitro experiments, this had 
to be repeated. When NKG2D was blocked, the soluble MICA concentration increased, 
however that increase was not significant (n=3, p>0.05, 1-way ANOVA) (Figure 4.24). 
Figure 4.24: MICA soluble expression in supernatants of cocultures of PC-3 cells with PBMCs in the 
presence or absence of aNKG2D. ELISA was performed for the detection of soluble MICA in the 
supernatant of the allogeneic cocultures, of PC-3 cell line with or without non-adherent PBMCs, in the 
presence or absence of IL-2 (10ng/ml) or IL-15 (2.5ng/ml), a) with or without blocking antibodies 
against NKG2D (10μg/ml) and MICA (5μg/ml) or b) their corresponding IgG1 (10μg/ml) and IgG2b 





In cocultures of non-adherent PBMCs with the LNCaP cell line, IL-15, in the presence of non-
adherent PBMCs, significantly downregulated the MICA soluble expression, when compared 
to control or IL-2. This decrease was consistent among all samples and was independent of 
the NKG2D or of the MICA blocking (n=3, *p<0.05, **p<0.01, ***p<0.001, ****p<0.00001, 1-
way ANOVA) (Figure 4.25). 
 
 
Figure 4.25: MICA soluble expression in supernatants of cocultures of LNCaP cells with PBMCs in the 
presence or absence of aNKG2D. ELISA was performed for the detection of soluble MICA in the 
supernatant of the allogeneic cocultures, of LNCaP cell line with or without non-adherent PBMCs, in 
the presence or absence of IL-2 (10ng/ml) or IL-15 (2.5ng/ml), a) with or without blocking antibodies 
against NKG2D (10μg/ml) and MICA (5μg/ml) or b) their corresponding IgG1 (10μg/ml) and IgG2b 





In order to assess the mechanism of action of IL-15 in our coculture model of immune 
effector cells with PCa cell lines, we focused on its ability to activate and expand NK cells; 
therefore the effects of IL-15 on NKRs and their associated ligands on PCa cells were 
examined. Physiologically, low amounts of IL-2 should be present in the prostate; therefore 
we aimed to mimic the prostate microenvironment, by studying the effects of IL-15 in the 
presence of low concentration of IL-2, apart from IL-15 alone. 
 
Initially the effects of IL-2 and IL-15 on NKRs when non-adherent PBMCs were 
cultured alone were assessed; IL-2 did not affect expression of any of the receptors when 
compared to control (no cytokine), however in the presence of IL-15, the expression of 
KIR2DL2, NKp46 and DNAM-1 was highly upregulated, when compared to control or IL-2. 
These data are in compliance with existing literature, which suggests that IL-15 increases the 
expression of DNAM-1 (Hromadnikova, Li et al. 2016) as well as NKp30, NKp44 and NKp46  
(de Rham, Ferrari-Lacraz et al. 2007). 
 
Regarding the NKG2D receptor, one of the best-characterised and investigated aNKRs,  
different studies have found that IL-15 can either have no effect on its expression (Muntasell, 
Magri et al. 2010) or they can upregulate it, enhancing the cytotoxicity of NK cells 
(Sutherland, Chalupny et al. 2002, Wu, Higgins et al. 2004). 
When non-adherent PBMCs were cocultured with PC-3 cells, the presence of IL-2 did not 
affect any of the receptors expressed, whereas in the presence of IL-15 NKG2D was 
upregulated, when compared to control and IL-2. In the cocultures with LNCaP cells the 
presence of IL-2 only, upregulated DNAM-1 expression by NK cells, whereas IL-15 
downregulated NKp30 expression, but upregulated KIR2DL2 and DNAM-1 as well. Although a 
decrease in the expression of natural cytotoxicity receptors would be expected to result in a 
decreased activity of the NK cells, it is possible that the inhibition of NKp30 by IL-15 and not 
IL-2 is a more significant finding which may explain the effect of IL-15 on NK cell activity. 
However NK cells are activated to kill both PC-3 and LNCaP cells in the presence of IL-15 and 
therefore the significance of the decreased expression of NKp30 in cocultures with LNCaP 
and not PC-3 cells is not clear. Due to the complexity of the above controversial findings and 
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also due to contradicting literature on the effects of cytokines on these receptors, we 
decided to examine the corresponding ligands of these NKRs on PCa cells. 
 
None of the ligands’ expression was significantly changed on the PCa cell lines when 
they were cultured without lymphocytes, in the presence of either IL-2 or IL-15 cytokines, 
when compared to control (see appendix 1). However, in cocultures of non-adherent PBMCs 
with PC-3 cells, the presence of IL-15 downregulated the expression of ULBP1 (ligand for the 
receptor NKG2D), when compared to control and IL-2. In cocultures with LNCaP cells, the 
presence of IL-15 (and not of IL-2) additionally highly downregulated the expression of MICA, 
Nectin-2 (for the receptors NKG2D and DNAM-1 respectively) and HLA Class-I Bw4 (for the 
receptor KIR3DL1). 
 
The downregulation of MICA, Nectin-2 and ULBP1 on PCa cells cultured with lymphocytes in 
the presence of IL-15 is also a controversial finding. Ligands for NKG2D are thought to 
activate NK cells through NKG2D when expressed on tumour cells and downregulation of 
these ligands is thought to be associated with cancer progression (de Kruijf, Sajet et al. 2012). 
Furthermore, in two separate studies on coeliac disease patients, it was found that the 
overexpression of IL-15 in intestinal cells upregulated MICA, enhancing the cytotoxicity of the 
intraepithelial lymphocytes (IELs) in an NKG2D dependent manner (Mention, Ben Ahmed et 
al. 2003, Meresse, Chen et al. 2004). Another study showed that the dendritic cell (DC) 
upregulation of MICA in response to IL-15 contributes to a poor DC-NK cross-talk, resulting in 
dampened NK cell activation, during a Hepatitis C viral infection (Jinushi, Takehara et al. 
2003). 
 
In addition to the cell surface expression, some of these NKG2D ligands can be shed 
or excreted from cells, by protein cleavage or even in an exosome form; cancer cells are also 
thought to evade NK cell cytotoxicity by shedding of these ligands (Raulet, Gasser et al. 2013). 
Soluble MICA has been found in sera of patients with various cancer types, such as colorectal 
cancer (Jinushi, Hodi et al. 2006), liver cancer (Jinushi, Takehara et al. 2005), epithelial 
cancers (Groh, Rhinehart et al. 1999) and PCa (Wu, Higgins et al. 2004). Soluble forms of 
ULBP1, ULBP2 and ULBP3 were also found on the supernatants of gastric tumour cell lines, as 
well as in sera of patients with haematopoietic malignancies (Song, Kim et al. 2006, 
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Waldhauer and Steinle 2006). The presence of soluble ligands in sera of cancer patients may 
correlate with poor prognosis of the disease, as in the case of soluble ULBP2 which correlated 
with poor prognosis of melanoma (Jinushi, Hodi et al. 2006). 
 
Decreased surface expression of the MICA, ULBP1, Nectin-2 and HLA-I Bw4 ligands in 
the presence of IL-15 in the coculture model were found, hence it was hypothesised that IL-
15 might also be inhibiting secreted forms of these ligands which resulted in an increase in 
NK cell activity. It was therefore investigated whether the presence of IL-15 was modifying 
the shedding of these ligands, by collecting supernatants from the allogeneic coculture 
models of non-adherent PBMCs with PC-3 or LNCaP cells. 
It was observed that IL-15 did not alter the soluble expression of Nectin-2 in the presence or 
absence of PBMCs compared to control or IL-2, whereas in supernatants from cocultures of 
lymphocytes with either PC-3 or LNCaP, IL-15 was inhibiting the secreted form of MICA, when 
compared to control or IL-2, unlike in cultures of PC-3 or LNCaP cells alone. LNCaP cells seem 
to expand NK cells better than PC-3 cells in the presence of IL-15. This may be because there 
is less MICA shed from LNCaP cells, and this is decreased by IL-15. 
 
NKG2D and MICA were subsequently blocked in the in vitro allogeneic system in order 
to investigate whether that would affect the NK cell expansion and cytotoxicity towards the 
PCa cells. Supernatants were collected so that soluble expression of MICA was studied, when 
NKG2D and MICA were blocked. 
Despite using several different concentrations of MICA blocking antibody that were 
suggested by the purchasing company and by literature, the MICA was not blocked in the 
allogeneic coculture model, which could be due to the poor antibody production; due to 
shortage of time, testing of more neutralising antibodies was not possible. However, NKG2D 
was successfully blocked when non-adherent PBMCs were cultured alone and in the 
presence of PC-3 or LNCaP cells. The presence of IL-15 significantly expanded both NK and 
NKT cells when compared to control or IL-2, in the absence or presence of PCa cells. As it was 
also shown in previous experiments, the presence of IL-15 and of the PCa cell lines increases 
the expansion of NK and NKT cells even more, when compared to cultures of immune 




We were unable to replicate our initial experiments (figure 4.7) where NKG2D expression was 
significantly increased in the presence of IL-15, when non-adherent PBMCs were cocultured 
with PC-3 cells, with that shown in figure 24a; despite observing an increase in the 
expression, significance is not reached, but with a few more experimental repeats, the 
significance could be reached. 
Additionally, on figure 4.10h the NKG2D expression by NK cells in the presence of IL-15 in 
cocultures with LNCaP cells seems to be similar to those of the control, however in the 
blocking experiments (figure 4.18), IL-15 seems to upregulate the NKG2D expression. From 
these results with the two cell lines, there is a trend observed, where IL-15 increases the 
NKG2D expression by NK cells, but in some cases the results have not reached significance, 
which indicates that more experiments should be done, as donor to donor, the amount of NK 
cells and of NKRs varies. 
 
Blockade of NKG2D seemed to have been successful, since the expression of NKG2D by NK or 
NKT cells was minimal, both when PBMCs were cultured alone and in cocultures with PCa cell 
lines and the neutralising aNKG2D antibody. The addition of aNKG2D neutralising antibody 
did not affect the expansion of NK or NKT cells in cocultures of non-adherent PBMCs with PC-
3 or LNCaP cells in the presence of IL-2 or IL-15. It is important to note however, that when 
aNKG2D antibody was added in the cocultures of non-adherent PBMCs with either of the cell 
lines, there was a decrease of NK expansion observed, compared to cocultures and IL-15 
where NKG2D was not blocked. 
The blockade of NKG2D did not affect the NK cytotoxicity towards the PCa cells; IL-15 
increased the percentage of apoptotic cancer cells in cocultures with PC-3 or LNCaP cells, 
with or without the NKG2D blocking antibody, when compared to control or IL-2. Therefore 
the IL-15 mediated increase in NK cell cytotoxicity towards the tumour cells is not affected by 
NKG2D. 
 
As mentioned, MICA was not successfully blocked on the PCa cell surface in cultures 
of PCa cells alone or in the cocultures with non-adherent PBMCs, however the supernatants 
from these samples were collected and also examined for the soluble expression of MICA. 
When PC-3 cells were cultured alone, there was a non-significant decrease observed in the 
MICA soluble expression in the presence of IL-2 and IL-15 compared to control. However, in 
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the presence of non-adherent PBMCs, the decrease in MICA concentration was substantially 
inhibited in the presence of IL-15. Neither the blockade of NKG2D, nor that of MICA had any 
effect on the MICA soluble expression in the presence or absence of cytokines. 
When LNCaP cells were cultured alone, there was a non-significant increase observed in the 
MICA soluble concentration in the presence of IL-2 and IL-15 compared to control. In the 
presence of PBMCs though, the MICA concentration was highly decreased in the presence of 
IL-15, when compared to control and IL-2, moreover that decrease was observed even in the 
presence of NKG2D and MICA blocking antibodies. 
 
Taking all these results into account, it is proposed that the presence of IL-15 highly 
expands the NK cells and enhances the cytotoxicity towards the PCa cells in the allogeneic 
coculture model of non-adherent PBMCs with PCa cell lines, by upregulating the NKG2D 
receptor expression, with a concomitant decrease in the surface and soluble expression of its 
ligand MICA. An increased interaction between NKG2D and MICA may be occurring due to 
the decrease in shed MICA which acts to inhibit NK cell activation. Further experiments to 
block NKG2D or MICA through SiRNA or gene knockouts may be needed to further validate 
the role of NKG2D and MICA on this model.  Also it may be worth exploring the role of the 
other ligands (e.g. HLA Class I Bw4), on the expansion and cytotoxic potential of IL-15 

















Cytotopic modification of recombinant human IL-15 and two 
antibodies against checkpoint inhibitor proteins and testing their 
















5.1 Introduction  
 
Non-cell based immunotherapies that are currently in use for many types of cancers 
(e.g. IL-2 for metastatic breast cancer) are administered systemically and can be extremely 
toxic and because of that they are only suitable for patients that are refractory to any other 
type of treatment (Fehniger, Cooper et al. 2002).  For solid tumours , their localisation to the 
primary cancerous lesion however, would both increase their efficacy and lower their 
toxicity. Furthermore, when considering such agents for immunotherapies, it is vital to 
consider their action at the site of the lesion where the immune system is most 
compromised. Many cytokines will have no effect when injected into this immunosuppressive 
environment based on our preliminary in vitro coculture data.  
  
Dr Richard Smith at King’s College London has developed a unique technology that can 
localise any protein or peptide to cell membranes. This technique is known as cytotopic 
modification and can be used to construct  proteins or peptides with amphiphilic (peptides 
containing both hydrophobic and hydrophilic regions) peptide-tails for tumour localisation 
(Smith and Smith 2001). Briefly, the protein of interest is attached to a “tail” molecule 
consisting of a myristoyl group and a cationic peptide sequence terminated with an activated 
thiol group that can link to free cysteines in the protein of interest (Smith and Smith 2001) 
(Figure 5.1). The technology has been successfully used to create a tailed CR1-fragment 
(APT070, Mirococept), which tethers to cell membranes and inhibits complement in situ 
more effectively than soluble CR1 (Patel, Smith et al. 2006); Mirococept is now in phase II 






Figure 5.1: Illustration of the tail. The ‘tail’ is comprised of (a) two myristoyl chains, that can build-in 
spontaneously to the hydrophobic portion of the cell membrane, which are attached to (b) a 
positively charged peptide: that interacts with the negatively charged hydrophilic portion of the cell 
membrane, securing the tail binding to the membrane and (c) a thiol group, which connects the tail to 
the peptide of interest (IL-15). 
 
This cytotopic technology can be applied to immunotherapeutic proteins such as cytokines so 
that these can be localised within tumour lesions and break tolerance within this 
immunosuppressive microenvironment. Such an approach can have two advantages – firstly 
– systemic toxicity of these agents is avoided. Secondly, less of these agents are required to 
induce a potent immune response. This has been previously seen when IL-2 was injected in 
situ into melanoma skin lesions in patients resulting in the clearance of distant metastases 
(Johnson, Lum et al. 2008).  
 
Based on the above, the aim of this project was to determine the efficacy of novel 
immunotherapeutics both as monotherapy and in combination, on the ability of NK and NKT 
cells to kill prostate tumour cells.  
Three agents: IL-15 and two immune checkpoint inhibitor antibodies named PTL033 and 
PTL035 (according to the nomenclature on our laboratory), were chosen to be studied in the 
context of immunotherapy for PCa. They were chosen due to previous studies showing their 
effectiveness in treating PCa in preclinical studies using mice (Yu, Steel et al. 2012), and in the 
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clinic. In our preliminary data we have also shown that IL-15 is the only cytokine from a panel 
of therapeutic Th1 cytokines that can induce the expansion of NK, NKT and CD8 T cells in the 
presence of PCa cells.  
Dr Dorota Smolarek from the Protein Therapeutics Laboratory created a novel form of IL-15, 
so-called tailed IL-15, and the two immune checkpoint inhibitor antibodies using Dr Richard 





























5.2.1 Confirmation of the cytototopic modification and of the cell membrane 
tethering of a) IL-15 and of b) the immune checkpoint inhibitor antibodies 
 
a) The human IL-15 tailing was confirmed by a variety of methods: by observing a molecular 
mass shift in gel electrophoresis of the untailed and tailed protein, using a tail that had been 
labelled with a fluorophore - FAM (Carboxyfluorescein) and by western blot analysis using an 




Figure 5.2: Visualisation of tailed IL-15: Visualisation of tailed IL-15. Gel electrophoresis followed by 
silver nitrate staining, Western blot analysis and UV light were employed for the visualisation of the 





The ability of tailed IL-15 to bind to cell membranes was shown using flow cytometry 
and sheep red blood erythrocytes or Jurkat cells. These cell types were chosen as they do not 
have receptors or proteins that can be bound by the untailed IL-15. Binding was assessed by 
flow cytometric analysis of the binding of IL-15 to these cells as detected by fluorophore 
labelled antibody to IL-15 (PE labelled anti-IL-15) (Figure 5.3). 
 
 
Figure 5.3: Confirmation of cell membrane binding of tailed IL-15 by flow cytometric analysis with 
staining detected by PE-labelled anti-IL-15. Little or no binding is seen with untailed IL-15 either on 
sheep red blood cells (Left panel) or Jurkats (right panel). Similar results were obtained with 30 mins 
or 24 hr incubation of tailed IL-15 on Jurkat cells (Right panel) showing that it can be retained on cell 
membranes through the tail portion of the molecule for a significant period of time. Internalisation is 
therefore slow allowing significant cell-surface binding and presentation for activity. 
 
b) Murine antibodies against immune checkpoint inhibitor proteins were conjugated to the 
tail (prepared by formation of disulphide- bridge between the tail and murine antibodies 
using 2-iminothiolane, as described in section 2.2.4.2 and 2.2.4.3). In order to confirm that 
the cytotopic modification was achieved, the tailed protein was visualised using SDS-PAGE 
electrophoresis followed by staining with Safestain™ (GE Healthcare) or UV light, where tail 
was FAM labelled (figure 5.4). 
To test the ability of the tailed PTL033 and PTL035 to bind to cell membranes Jurkat cells 
were used, a T-cell line which does not have on their surface any receptors or proteins that 
can be bound by these proteins. Binding was assessed by flow cytometric analysis of the 
binding of the two modified antibodies to Jurkat cells, as detected by fluorophore labelled 









Figure 5.5: Confirmation of cell membrane binding of tailed PTL035 and PTL033. Flow cytometric 
analysis with staining detected by PE-labelled anti-rat IgG2b (in regards to PTL035) and APC labelled 
anti-hamster IgG (in regards to PTL033) showed little or no binding with untailed proteins, but 






5.2.2 Confirmation of activity of tailed IL-15, tailed PTL033 and tailed PTL035 in 
vitro 
In order to measure the activity of tailed IL-15, a cell proliferation assay with a murine 
cytotoxic T cell line (CTLL-2) was performed. A higher CTLL-2 proliferation was observed and 
at lower concentrations of cytokine when incubating them with tailed IL-15, compared to the 
non-tailed (Figure 5.6). 
 
 
Figure 5.6: Confirmation of activity of tailed IL-15 by MTS. A cell proliferation assay (MTS) was 
performed in order to confirm the ability of tailed IL-15 to expand the CTLL-2 cell line. Higher 














The activity of tailed IL-15 was then confirmed using human and murine NK lymphocytes, 
which were incubated with tailed and non-tailed protein to induce their expansion. After 7 
days of culture, the NK cell population was analysed by flow cytometry and it was shown that 
the tailed IL-15 has equivalent or greater ability to expand human NK cells (detected by 
staining of CD56+CD3- cells ) and murine NK cells (detected by staining of NK1.1+CD3- cells) 
compared with non-tailed IL-15 (Figure 5.7).  
 
 
Figure 5.7: NK cell expansion by tailed IL-15 confirming it activity. Comparison of NK expansion in a 
human PBMC population (A) and a murine splenocyte population (B) treated for 7 days with IL-2 (100 
units per ml) , Peprotech IL-15, untailed G-IL-15 and tailed G-IL-15 (2.5 ng/ml each). Tailed IL-15 has 
equivalent or better activity in expanding NK cells compared with untailed IL-15 from Genscript or a 












The activity of the tailed antibodies PTL033 and PTL035 was studied by measuring re-
constitution of IL-2 secretion in the Jurkat cell based model (PTL033), or by prevention of 
binding between receptor and ligand on EL-4 cells (PTL035), using flow cytometry and 
recombinant proteins. It was observed that the tailed PTL033 has equivalent activity to the 
non-tailed antibody and the tailed PTL035 has a greater activity than non-tailed PTL035 
(figure 5.8). 
 
Figure 5.8: Confirmation of activity of tailed PTL033 and of tailed PTL035. Comparison of activity of 
tailed and untailed PTL033 antibody in restoring IL-2 secretion by activated Jurkat cells and of tailed 















5.2.3 Confirmation of activity of tailed IL-15, tailed PTL033 and tailed PTL035 in 
vivo in C57BL/6 mice challenged with the TRAMP-C2 carcinoma cell line  
The efficacy of tailed IL-15 to inhibit tumour growth was determined by an in vivo 
subcutaneous prostate cancer tumour challenge model in C57BL/6 mice. A previous study 
shows that IL-15 together with two antibodies to immune checkpoints can inhibit 
subcutaneous tumour growth in this model by up to 70% in 45 days (Yu, Steel et al. 2012) . 
Initially, the optimal dose of injected TRAMP-C2 cells was determined (figure 5.9); three 
doses of different cell number concentrations were assessed for the quickest tumour growth. 
The concentration of 1x107 cells per injection resulted in a quicker tumour formation; 
however it was not significantly different to the other doses. The dose of 5*106 cells in total 
was used for further tumour cell challenges in mice as it has been previously used in 
literature (Kwon, Foster et al. 1999). 
 
 
Figure 5.9: Dose response optimisation experiment for the in vivo tumour cell challenge. Six 6-8 weeks 
old C57BL/6 mice were subcutaneously injected with either 1*106 total number of TRAMP-C2 cells, or 
5x106 or 1x107 cells. There was no significant difference observed in the time or size of the tumour 





Following this experiment, the next step was to verify the in vivo activity of tailed and 
untailed compounds. Thirty 6-8 week old C57BL/6 mice were subcutaneously injected with 
5x106 TRAMP-C2 tumour cells in sterile PBS. At Day 12 post tumour injection, the animals 
were divided into three groups:   
- Group 1 (control) was injected subcutaneously at the tumour site with sterile PBS;  
- Group 2 was injected with untailed IL-15 and untailed murine antibodies to immune 
checkpoint inhibitors.  
- Group 3 was injected with tailed IL-15 and the tailed PTL033 and PTL035  
Tumour growth was measured up to 3 times per week for 73 days. A complete clearance of 
tumours by day 73 in the animals given just one injection of the cocktail of tailed IL-15, 
PTL033 and PTL035 was observed (Figure 5.10).  
 
Figure 5.10: In vivo tumour cell challenge experiment. Thirty 6-8 weeks C57BL/6 mice were 
subcutaneously injected with 5x106 cells TRAMP-C2 cells in sterile PBS. At day 12 (D12) post tumour 
injection, the animals were divided in 3 groups; ten were injected with PBS at the site of the tumour 
(Group 1- control), ten with 5μg of untailed IL-15,100 µg PTL033 and 100 µg  PTL035 (Group 2) and 
ten with the tailed version of the cocktail (Group 3). TRAMP-C2 tumour growth is shown to be 
completely cleared in the tailed cocktail group after 73 days whereas tumours were still present in 



















5.2.4 Histological analysis of the tumour tissue for the detection of infiltrating 
immune effector cells 
Histological analysis of the tumour tissue obtained from the animals showed 
increased necrosis in the tailed injection group as seen with H and E staining and increased 
infiltration of NK cells and CD8 T cells compared to untailed and PBS groups (Figure 35). 
 
 
Figure 5.11: Histological analysis of tumour tissue. Staining of tumours obtained from animals injected 
intra-tumourally with tailed cocktails of IL-15, PTL033 and PTL035, untailed cocktails of IL-15, PTL033 
and PTL035 or PBS. Tissues were stained either with haematoxylin and eosin (H&E) or with antibodies 
to NK1.1, and CD3 (top panel Green and red respectively), CD8 (middle panel) or CD4, CD25 and 
FOXP3 (lower panel, Blue, green and red respectively). Infiltration of NK cells and CD8 T cells are 






The in vitro coculture models, both allogeneic and syngeneic that were developed in 
our lab, have enabled us to test novel immunotherapeutics, using Dr Richard’s Smith tailed 
protein agents. This protein modification technology, has been successfully used previously 
to create a tailed CR1 fragment (Mirococept), which is now on phase II kidney transplant 
trials (Patel, Smith et al. 2006).  
The IL-15 protein was attached to a tail as observed by silver nitrate staining and western 
blots and flow cytometry confirmed that the tailed IL-15 was capable of binding to cell 
membranes. Thereafter, the in vitro activity of the tailed IL-15 protein was investigated 
through its ability to induce CTLL-2 cell proliferation- as measured by a previously described 
cell proliferation technique, MTS (Soman, Yang et al. 2009) - and through its ability to induce 
human and murine NK cell proliferation.  
A fully functional tailed IL-15 form was produced; it induced the proliferation of the CTLL-2 
cell line and of the murine and human NK cells, when compared to the control (no cytokine 
addition), or at similar or higher levels than the non-tailed form of IL-15. Furthermore, a 
lower concentration of tailed IL-15 was needed to observe the above effects. This cytotopic 
technology enables any protein of interest to become modified to attach to the cell 
membranes and exert its effect for a much prolonged period. Consequently, the finding that 
tailed IL-15 has either similar or better effects to the non-tailed IL-15, is a promising result, 
suggesting that the expansion of NK, NKT and CD8 T cells and the killing of the PCa cells could 
be much higher, if this protein is injected at the site of the tumour in vivo.  
   
Two antibodies to immune checkpoint inhibitors were chosen to be part of a cocktail 
of drugs that were used further in an in vivo mouse model. These two antibodies were also 
attached to a tail and the cytotopic modification was confirmed by flow cytometry. The 
activity of the PTL033 was studied by measuring re-constitution of IL-2 secretion in the Jurkat 
cells, whereas that of the PTL035 was studied by prevention of binding of receptor and ligand 
on EL-4 cells, using flow cytometry. The results were very promising since equal or better 





An in vivo tumour challenge model of C57BL/6 mice injected with TRAMP-C2 tumour 
cells was employed for the testing of the efficacy of the cocktail of tailed drugs (IL-15, 
PTL033, PTL035). 
Before proceeding with this experiment though, a dose response experiment was performed, 
in order to find the optimal dose of injected TRAMP-C2 cells leading to the fastest tumour 
development. Various different cell concentrations have been previously used in literature on 
tumour cell challenge experiments (Kwon, Foster et al. 1999), however                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
we chose to use a concentration of 5x106 total numbers of cells, since all three different 
concentration of cells producing a similar result.  
To assess the efficacy of the three tailed proteins, thirty C57BL/6 mice were subcutaneously 
injected with the optimised dose of TRAMP-C2 cells and at day 12 they were again injected 
subcutaneously at the site of the tumour with either PBS (control- group 1) or a cocktail of 
the three therapeutic agents- IL-15, PTL033 and PTL035 either in untailed (group 2) or tailed 
form (group 3). Our results showed that the tumours were cleared by day 73 in all mice 
injected with a single injection of the tailed cocktail, unlike the other two groups of mice. 
Nevertheless, the mice that were injected with the untailed cocktail of drugs also showed a 
regression in their tumours, which was significant when compared to the control group, but 
as the tailed proteins have the ability to attach to the cell membranes, they are also able to 
exert their functions for a prolonged period of time; hence in the group of mice that were 
injected with tailed drugs, the tumours had all disappeared.  
In addition, tumour tissue was collected from each group of mice to test for the infiltration of 
immune effector cells. The H and E staining showed increased necrosis in the tailed injection 
group and the immunohistochemistry, showed increased NK and CD8 T cell infiltration in the 
tissue obtained from the tailed group of mice, when compared to the PBS group or the 
untailed group.   
This result proved the unique efficacy of tailed IL-15 in vivo as well as in vitro, although the in 




































6.1 Discussions and Conclusions 
 
In this project we aimed to create in vitro and in vivo models of tumour- immune 
effector cell interaction and tumour cell killing which would enable us to identify, test and 
optimize novel immunotherapeutics. Our focus was to create non-cell based 
immunotherapies, such as cytokine treatments, which would be injected at the site of the 
tumour lesion, in order to overcome the immunosuppressive prostate tumour 
microenvironment, to enhance the efficacy of those and to avoid the toxic side effects that 
are observed upon systemic injection of a cytokine.  
The in vitro creation of an allogeneic coculture model of immune effector cells and prostate 
cancer cell lines, both metastatic and non-metastatic, that was designed for these 
experiments, resembles the PCa microenvironment and it has enabled us to study the effects 
of a panel of therapeutic Th1 cytokines, in the immune effector cell proliferation and 
function. The cytokines studied included IL-2, IFNγ, IL-12, IL-15 and IL-21.  
 
Preliminary data by Mr. Oussama Elhage in our laboratory, has shown that in this 
allogeneic coculture system, IL-15 was the most potent activator of NK, NKT and CD8 T cells 
aiding the expansion of these cells and the killing of the PCa cell lines, when compared to the 
other therapeutic Th1 cytokines that were investigated (Elhage, Galustian et al. 2011). 
However, as there was only one coculture ratio of immune effector cells to PCa cells studied 
(8:1 E:T ratio), we aimed to investigate, whether other E:T ratios would produce different 
effects on the expansion of these immune effector cells and their cytotoxicity. In the 
literature there have been multiple E:T ratios tested (Marten, Renoth et al. 2001, Balsamo, 
Vermi et al. 2012, Shi, Fan et al. 2014), so in our allogeneic coculture system, both with PC-3 
and LNCaP cell lines, three different ratios (8:1, 4:1, 2:1) were tested for the ability of IL-15 to 
expand NK, NKT and CD8 T cells (naïve, not primed) and increase the perforin and CD107a 
expression by these cells. Additionally, the optimal concentration of IL-15 (0.5-25ng/ml) that 
would produce the highest percentage PCa cell death by the immune effector cells was 
investigated, as well as the optimal coculture E:T ratio (those tested included 20:1, 8:1, 4:1, 
2:1, 1:1, 0.5:1). 
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Taking both the phenotypic and the cell killing results into account, it was decided that the 
optimal ratio for coculturing the immune effector cells with the PCa cell lines (for both PC-3 
and LNCaP) was 4:1 and the optimal concentration of IL-15 was 2.5ng/ml. Although the 8:1 
coculture ratio had given similar results to the 4:1 ratio, and sometimes even better results 
when considering the CD107a expression by NK cells (in cocultures with PC-3 cell line), the 
PCa cell killing was considerably better at the 4:1 E:T ratio in cocultures with both cell lines. 
On the results presented in this thesis, although the CD8 T cells were expanded in the 
presence of IL-15 when the immune effector cells were cultured alone, in cocultures with PC-
3 or LNCaP cell lines, IL-15 did not increase the expansion of CD8 T cells, unlike what was 
previously shown by Elhage et al. (Elhage, Galustian et al. 2012). This difference may be due 
to the fact that in the preliminary experiments the concentration of IL-15 that was used was 
25ng/ml, whereas in the experiments of this thesis, the concentration used was 2.5ng/ml. It 
was shown by Ms Fiona Watkinson from the Protein Therapeutics Laboratory, that the 
highest expansion of NK cells is observed in the presence of 2.5ng/ml IL-15, and at 
concentrations above that, the NK cells expand less. It may be that CD8 T cells need a higher 
concentration of IL-15 to expand rather than 2.5ng/ml that was used for our work, hence the 
discrepancy found between the preliminary and this thesis’ results. Furthermore, it was also 
shown by Elhage et al. in a separate study investigating the effects of depleting CD56+ cells 
and CD8 T cells on IL-15 mediated effector-cell induced PCa cell killing and expansion of CD8 
and CD56 cells respectively within the cocultures, CD8 T cell depletion enhanced the NK cell 
mediated PCa cell killing, suggesting that CD8 T cells may hinder the CD56+ cell cytotoxic 
activity (Elhage, Sakellariou et al. 2015). Hence our finding that IL-15 does not expand the 
CD8 T cells in cocultures of immune effector cells with PC-3 or LNCaP cell lines, does not 
affect the PCa cell killing which is attributed to NK cells.  
 
Following the optimization of the allogeneic coculture model’s E:T ratio, a syngeneic 
coculture model was set up, in order to investigate whether alloreactivity is aiding the 
expansion of NK and NKT cells. The syngeneic coculture model was comprised of murine NK- 
or T- enriched cells derived from the spleen of a C57BL/6 mouse, cocultured with the TRAMP-
C1 cell line; a PCa cell line also derived from the transgenic adenocarcinoma of the C57BL/6 
mouse prostate. Similar to the allogeneic model, E:T ratios were investigated; IL-15 
significantly increased the killing of the TRAMP-C1 cells by the NK cells at E:T ratios of 1:1, 2:1 
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and 4:1. However, taking into account that the highest NK cell expansion by IL-15 was 
observed at 4:1 E:T ratio, it was decided to use that ratio for further experiments. As a 
control measurement, it was investigated, whether IL-15 was toxic towards the TRAMP-C1 
cells, without addition of the immune effector cells. So, TRAMP-C1 cells were cultured alone 
at different cell concentrations with or without the addition of IL-15: it was observed that IL-
15 did not enhance the TRAMP-C1 killing, confirming that it modulates only the immune 
effector cell proliferation and function of these in coculture models.  
 
NK- or T- enriched cells were cocultured in the presence or absence of TRAMP-C1 cells, in the 
presence or absence of a panel of therapeutic Th1 cytokines (i.e IL-2, IL-12, IL-15, IL-21, IFNγ) 
as the allogeneic coculture model was designed. It was found that indeed IL-15 was the only 
cytokine that highly expanded the NK, NKT and CD8 T cells, when compared to the control 
(no cytokine) or to the other Th1 cytokines. IL-15 did not affect the T regulatory cells, as it 
was also shown in the preliminary data results from the allogeneic coculture model.  
IL-15 has been previously shown to enhance NK and T cell proliferation (Fehniger, Suzuki et 
al. 2001); (Gravisaco, Mongini et al. 2003, Sato, Sabzevari et al. 2011). However, to our 
knowledge we are the first group in the UK, to show that IL-15 is also active when effector 
immune cells are cultured in the presence of PCa cell lines.  
 
Based on the above observations, and as the NK cells bear receptors on their surface 
that regulate the killing of the target cells, it was investigated whether the IL-15 mechanism 
of action is through the modulation of inhibitory, activatory and natural cytotoxicity receptors 
on NK cells and their associated ligands on the PCa cells.  
 
NK cells bear a number of aNKRs and iNKRs on their surface that enable them to modulate 
immune responses and maintain tissue homeostasis. The cytolytic activity of NK cells is 
regulated by positive signalling of the aNKRs which trigger cell lysis, and by negative signalling 
of the iNKRs that prevent cell lysis. In this study, we aimed to investigate how IL-15 
modulates the ability of NK cells to kill PCa cells and therefore we investigated the IL-15 
effects on three KIR receptors (KIR3DL1, KIR2DL1, KIR2DL2) and on five aNKRs (DNAM-1, 
NKG2D, NKp30, NKp44, NKp46), using the allogeneic coculture model and observing the 
percentage expression of each receptor by the NK cells. 
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Physiologically, low amounts of IL-2 should be present in the prostate; therefore we aimed to 
mimic the prostate microenvironment, by studying the effects of IL-15 in the presence of low 
concentration of IL-2, apart from IL-15 alone. 
 
Initially the effects of IL-2 and IL-15 on the receptor expression by NK cells, when PBMCs are 
cultured alone, were investigated and it was found that IL-2 did not have any significant 
effect on any of the receptor expression when compared to the control (no cytokine), 
whereas IL-15 highly upregulated KIR2DL2, NKp46 and DNAM-1 expression. However, in the 
presence of the PC-3 cell line, IL-15 did not seem to affect the expression of any of these 
receptors that it upregulated on PBMCs, but it only highly upregulated the expression of 
NKG2D. In the presence of LNCaP cells though, IL-15 still upregulated the KIR2DL2 expression 
as well as that of DNAM-1 and it downregulated the expression of NKp30.  
Our finding that in cocultures of immune effector cells with PC-3 cells, IL-15 highly increases 
the NKG2D expression, suggests that IL-15 increases the NK cytotoxicity in an NKG2D 
dependent- manner. The initial coculture data of immune effector cells with LNCaP cells 
(figure 4.10) did not show a significantly increased NKG2D expression by NK cells in the 
presence of IL-15, although when these experiments were repeated in figure 4.20, IL-15 
seemed to highly significantly upregulate NKG2D. This discrepancy may be due to donor to 
donor differences in the amount of NK cells and of the NKG2D per donor; the standard 
deviation in the first set of experiments is much larger when compared to the second set of 
experiments; hence it is assumed that variation in donor NK/NKG2D percentages gave a non-
significant result.  
The result of the second experiment (figure 4.20), where NKG2D expression is highly 
upregulated in the presence of IL-15, in cocultures with LNCaP cells, is in compliance with 
other published studies, where IL-15 has been shown, in two separate studies, to increase 
the NKG2D receptor in acute myeloid leukaemia patients with a concomitant increase in NK 
cytotoxicity against autologous leukemic blasts (Szczepanski, Szajnik et al. 2010) (Anguille, 
Van Acker et al. 2015). Additionally, other studies have suggested that IL-15 regulates the 
cytotoxic T lymphocytes’ activity by regulating the NKG2D pathway in an inflammatory 
environment, as in the case of tuberculosis (Tagaya, Bamford et al. 1996, Roberts, Lee et al. 




The increased expression of KIR2DL2 and of DNAM-1 by IL-15 is also in agreement with 
existing literature, which suggests that IL-15 increases the expression of DNAM-1 
(Hromadnikova, Li et al. 2016) as well as NKp30, NKp44 and NKp46  (de Rham, Ferrari-Lacraz 
et al. 2007), with a concomitant increase in the NK cytotoxicity.  
A decrease in the expression of natural cytotoxicity receptors would be expected to result in 
a decreased activity of the NK cells; NK cells are activated to kill both PC-3 and LNCaP cells in 
the presence of IL-15 and therefore the significance of the decreased expression of NKp30 
with LNCaP and not PC-3 cells is not clear. Due to the complexity of the above controversial 
findings and also due to contradicting literature on the effects of cytokines on these 
receptors, we went on to examine the corresponding ligands of these NKRs on PCa cells.  
 
The surface expression of the NKR ligands by the PC-3 or LNCaP cell lines was not 
significantly affected by the presence of IL-2 or of IL-15. However in cocultures of non-
adherent PBMCs and PC-3 cells, the presence of IL-15 significantly downregulated the 
expression of ULBP1 (a ligand for the NKG2D receptor), when compared to the effects of IL-2 
or of the control. In the case of cocultures with the LNCaP cell line, IL-2 did not have any 
effect on any of the ligands, whereas IL-15 significantly downregulated MICA and ULBP1 
(ligands for NKG2D), Nectin-2 (ligand for DNAM-1) and HLA-I Bw4 (ligand for KIR3DL1).  
IL-15 may be aiding the cytotoxic capacity of NK cells towards the LNCaP cells by increasing 
the expression of DNAM-1 in NK cells and decreasing the corresponding Nectin-2 ligand on 
LNCaP cells. Kritikou et al (2016) also suggested that increased DNAM-1 expression could 
lead to an increased tumour cell killing of cells that express that ligand, as was observed on 
B16 melanoma cells and RMA-S lymphoma cells (Kritikou, Dahlberg et al. 2016).  
The effect of IL-15 on KIR receptors and on their corresponding ligands is a poorly understood 
concept and there are limited or no previously published studies suggesting a putative effect 
of IL-15. It is important to note though, that NK cell cytotoxicity is triggered by the loss of 
MHC Class I on tumour cells (Moretta and Moretta 2004, Bachanova and Miller 2014), so 
possibly the high downregulation of HLA-I Bw4 by IL-15, signifies the increased cytotoxic 
activity of NK cells towards the PCa cells.  
Although the relationship between IL-15 and ULBP1 is another poorly researched area, a 
study by Sutherland et al. (2006) supports our theory, that IL-15 enhances the NK cytotoxicity 
towards the PCa cells by downregulating the ULBP1 ligand, as they have shown that in 
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C57BL/6 SCID mice that were challenged with EL-4 cells expressing the ULBP1 ligand, IL-15 
enhanced the tumour rejection, compared to the mice that were EL-4 control cells 
(Sutherland, Rabinovich et al. 2006).  
 
The effects of the NKG2D - MICA interaction in cancer have been at the centre of 
investigation for many years, resulting in ambiguous opinions (Zhang, Basher et al. 2015). In 
this project, we investigated this interaction in regards to IL-15 and aimed to understand 
what the mechanism of action of IL-15 is, as it is shown that IL-15 enhances the NK cell 
expansion and its cytotoxic activity towards the PCa cells in our allogeneic coculture model. 
Apart from investigating the expression of NKG2D and its ligand MICA at the surface of NK 
and PCa cells respectively, we investigated the concept of shedding of the ligand in a soluble 
form. It has been suggested that shedding of MICA by tumour cells promotes the tumour 
immune evasion (Groh, Wu et al. 2002, Doubrovina, Doubrovin et al. 2003, Raffaghello, 
Prigione et al. 2004, Wu, Higgins et al. 2004).  
Using the allogeneic coculture model of immune effector cells with PC-3 or LNCaP cells, we 
found that IL-15 a) increases the NKG2D surface expression in both coculture models, b) 
decreases substantially the MICA surface expression in the cocultures with LNCaP and when 
investigating the concept of shedding of this ligand in the supernatants of the cocultures of 
immune effector cells with PC-3 or LNCaP cells, and c) highly downregulates the soluble 
expression of MICA when compared to the control. Unfortunately, blocking of MICA in our 
coculture model was not successful, however blocking of NKG2D did not seem to affect the 
cytotoxicity of NK cells towards the PCa cells. A study that was published this year by Wu 
(2016) suggests that neutralizing the soluble sMIC in a humanized model of metastatic PCa, 
significantly reduced the prostate tumours and prevented metastasis (Wu 2016).   
 
Our study therefore proposes that IL-15 enhances the NK cytotoxicity towards the 
PCa cells in a coculture model of immune effector cells with PCa cell lines, which has been 
optimised to mimic the PCa microenvironment, by upregulating the NKG2D receptor 
expression and downregulating the surface and soluble expression of its ligand MICA.  
 
 Following the investigation of the mechanism of action of IL-15 we assessed its 
activity in vivo, as part of a therapeutic cocktail in C57BL/6 mice, challenged with TRAMP-C2 
170 
 
carcinoma cell line. IL-15 in combination with two antibodies to immune checkpoints (PTL033 
and PTL036) underwent a protein modification, using a technology developed in Dr Richard 
Smith’s laboratory called cytotopic modification; by this, the protein of interest is attached to 
a ‘tail’ molecule consisting of a myristoyl group and a cationic peptide sequence terminated 
with an activated thiol group that can link to free cysteines in the protein of interest (Smith 
and Smith 2001).  Applying this technology to immunotherapeutic proteins, enables them to 
be localised within the tumour lesions, breaking the tolerance within this immunosuppressive 
microenvironment, avoiding the systemic toxicity of these agents and inducing a potent 
immune response, even when less of these agents is used.  
Dr Dorota Smolarek from the Protein Therapeutics Laboratory cytotopically modified the IL-
15 and the two antibodies to immune checkpoints, which comprised the cocktail of drugs 
that was tested in vivo. Prior to that though, the activity of the tailed cocktail of drugs was 
tested using in vitro assays. The activity of tailed IL-15 and of PTL033 and PTL035 was shown 
to be either equal or better to the non-tailed forms of these agents, hence we proceeded 
with the in vivo tumour challenge experiment: C57BL/6 mice were subcutaneously injected 
with the TRAMP-C2 cell line and at day 12 they were again subcutaneously injected as close 
to the tumour as possible, either with PBS, or non-tailed forms of the cocktail of drugs or with 
the tailed forms of the cocktail. The growth of the tumour in the mice was monitored every 
one or two days, and by day 73 the mice injected with the tailed forms of the cocktail of 
drugs showed complete clearance of their tumours, unlike the other two groups of mice 
injected with PBS or untailed cocktail.  
Tumour tissue was collected from each mouse in every group that grew a tumour and the 
tissue was stained with H&E or for immune cell infiltration of NK, CD8 T and Treg cells. 
Increased tissue necrosis was shown by H&E on the tissue obtained from the tailed group, as 
well as increased NK and CD8 T cell infiltration, when compared to the other groups.  
 
Overall in this thesis, we have identified a cytokine, IL-15, that seems to be the most 
potent activator of NK, NKT and CD8 T cells, aiding their expansion and cytotoxic activity 
towards the PCa cells in an in vitro allogeneic coculture model of immune effector cells with 
PCa cells, which mimics the PCa immunosuppressive microenvironment. The mechanism by 
which IL-15 aids the cytotoxic activity of NK cells towards the PCa cells seems to be through 
the upregulation of the NKG2D receptor on the surface of NK cells, with a concomitant 
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downregulation of its ligand MICA both on the surface of the PCa cells and in a soluble form. 
When tested in vivo, a cocktail of IL-15 with two antibodies to immune checkpoints, that have 
been biochemically modified to localise at cell membranes, so called ‘tailed’, also seem to 
prove more efficacious, when compared to their non-tailed forms or control, as they 
completely clear the tumours from mice, only with a single injection of the tailed cocktail at 






























6.2 Future work 
The readout for NK cell expansion has been mainly based on the measurement of the 
CD56 percent expression within the population of non-adherent PBMCs in the human 
coculture model. However, it is reported that CD56 dim and bright populations have different 
functions, hence it would be reasonable to examine these in our human coculture models. 
We should also examine the effects and function of the CD16 dim and bright NK cells. 
Additional readouts for effector cell expansion for NK, NKT and CD8 T cells in the human 
coculture model and within the splenocytes enriched for NK cells or CD8 T cells should 
include the CFSE (Carboxyfluorescein succinimidyl ester) incorporation and Ki67 expression; 
both are dyes that marker cell proliferation.   
 
NK receptor and ligand experiments were performed using the in vitro allogeneic 
coculture model of non-adherent PBMCs with PCa cell lines. However in order to exclude any 
results that are attributed to alloreactivity in our model, these experiments should also be 
performed using the in vitro syngeneic coculture model.  
Although the proposed mechanism of action of IL-15 in enhancing the NK cell expansion and 
aiding its cytotoxicity towards the PCa cell lines, was suggested to be through the 
upregulation of the NKG2D receptor on NK cells with a concomitant decrease in the MICA 
surface and soluble expression on the PCa cell lines, MICA was not successfully blocked in our 
system; hence this should be further investigated, potentially using an even higher 
concentration of the blocking aMICA antibody and even by the purchase of a different 
neutralising antibody. Furthermore, it would be beneficial to investigate whether HLA-I Bw4, 
a NKR ligand that was highly downregulated by IL-15 provides an additional enhancement on 
the IL-15 activity.  
 
 The in vivo challenge experiment was only performed once, although 10 animals were 
used in each group giving a strongly significant result and should be repeated in the future. 
Unfortunately the time was a limiting factor from repeating the experiment more times since 
different variables had to be optimised (e.g. Needle size, specific C57BL/6 mouse strain) in 
order to achieve a desirable tumour size. Perhaps using a different tumour cell line, such as 
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RM9, a rapidly growing prostate tumour cell line, could provide us with a more potent mouse 
tumour challenge. 
The challenge model should also be repeated using the individual components of the 
therapeutic cocktail in tailed and non-tailed form. Yu et al. (Yu, Steel et al. 2012)  found that 
IL-15 alone did give a 50% reduction of tumour volume.  
Based on the proposed mechanism of action of IL-15, a next step should also be to tumour- 
challenge mice that are NKG2D knockouts and examine the effects of our tailed and non-


































PC-3 cells were cultured alone, in the presence of absence of IL-2 (1ng/ml or 10ng/ml) or of 
IL-15 (2.5ng/ml) with or without IL-2 (1ng/ml), in order to observe the levels of the ligand 
expression by this cell line and whether these are altered in the presence of IL-2 or IL-15 
cytokines. No significant change in any of the ligands’ expression by PC-3 cells was observed 
in the presence of cytokines, when compared to control (no cytokine addition) (n=3-5, 
p>0.05, 1-way ANOVA) (Figure A.1-4).  
 
Figure A.1 a-c: Expression of the NKG2D ligands, MICA, MICA/B and ULBP1 by PC-3 cells. PC-3 cells were 
cultured in the presence or absence of IL-2 (1 or 10ng/ml) and of IL-15 (2.5ng/ml) with or without IL-2 




Figure A.2 d,e : Expression of HLA Class I and HLA-ABC by PC-3 cells. PC-3 cells were cultured in the 
presence or absence of IL-2 (1 or 10ng/ml) and of IL-15 (2.5ng/ml) with or without IL-2 (1ng/ml) (n=4-




Figure A.3  f,g : Expression of HLA Class I Bw4 and HLA-G by PC-3 cells. PC-3 cells were cultured in the 
presence or absence of IL-2 (1 or 10ng/ml) and of IL-15 (2.5ng/ml) with or without IL-2 (1ng/ml) (n=3-





Figure A.4 h: Expression of the DNAM-1 ligand, Nectin-2, by PC-3 cells. PC-3 cells were cultured in the 
presence or absence of IL-2 (1 or 10ng/ml) and of IL-15 (2.5ng/ml) with or without IL-2 (1ng/ml)(n=4, 

















LNCaP cells were cultured alone, in the presence of absence of IL-2 (1ng/ml or 10ng/ml) or of 
IL-15 (2.5ng/ml) with or without IL-2 (1ng/ml), in order to observe the levels of the ligand 
expression by this cell line and whether these are altered in the presence of IL-2 or IL-15 
cytokines. No significant change in any of the ligands’ expression by LNCaP cells was observed 
in the presence of cytokines, when compared to control (no cytokine addition) (n=4, p>0.05, 
1-way ANOVA) (Figure A.5-8).  
 
Figure A.5 a-c : Expression of the NKG2D ligands, MICA, MICA/B and ULBP1 by LNCaP cells. LNCaP cells 
were cultured in the presence or absence of IL-2 (1 or 10ng/ml) and of IL-15 (2.5ng/ml) with or 




Figure A.6 d,e : Expression of HLA Class I and HLA-ABC by LNCaP cells. LNCaP cells were cultured in the 
presence or absence of IL-2 (1 or 10ng/ml) and of IL-15 (2.5ng/ml) with or without IL-2 (1ng/ml) (n=4, 







Figure A.7 f,g : Expression of HLA Class I Bw4 and HLA-G by LNCaP cells.  LNCaP cells were cultured in 
the presence or absence of IL-2 (1 or 10ng/ml) and of IL-15 (2.5ng/ml) with or without IL-2 (1ng/ml) 












Figure A.8 h : Expression of the DNAM-1 ligand, Nectin-2, by LNCaP cells. LNCaP cells were cultured in 
the presence or absence of IL-2 (1 or 10ng/ml) and of IL-15 (2.5ng/ml) with or without IL-2 (1ng/ml) 
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